

***Supplementary Information for:***

**Genetic Encoding of Three Distinct Noncanonical Amino Acids Using Reprogrammed Initiator and Nonsense Codons**

Jeffery M. Tharp,<sup>†</sup> Oscar Vargas-Rodriguez,<sup>†</sup> Alanna Schepartz,<sup>\*,§,||</sup> and Dieter Söll<sup>\*,†,‡</sup>

<sup>†</sup>Department of Molecular Biophysics & Biochemistry, Yale University, New Haven, CT 06520, United States

<sup>‡</sup>Department of Chemistry, Yale University, New Haven, CT 06520, United States

<sup>§</sup>Department of Chemistry, University of California, Berkeley, CA 94705, United States

<sup>||</sup>Department of Molecular & Cell Biology, University of California, Berkeley, CA 94705, United States

\*Correspondence should be addressed to Alanna Schepartz (schepartz@berkeley.edu)  
and Dieter Söll (dieter.soll@yale.edu)

## Contents

<b>Materials and Methods</b> .....	<b>3</b>
General .....	3
Safety Statement .....	3
Plasmid Construction .....	3
Protein Expression and Purification .....	5
<i>In vivo</i> sfGFP Reporter Assay .....	5
<i>In vitro</i> tRNA Aminoacylation .....	5
MaPyIRS N166/V168 Library Screening .....	6
Protein Labeling .....	6
Proteome Labeling .....	7
Cell growth analysis .....	7
Mass Spectroscopy .....	7
<b>Supplementary Figures</b> .....	<b>9</b>
Figure S1 .....	9
Figure S2 .....	9
Figure S3 .....	10
Figure S4 .....	10
Figure S5 .....	11
Figure S6 .....	12
Figure S7 .....	13
Figure S8 .....	14
Figure S9 .....	15
Figure S10 .....	16
Figure S11 .....	17
Figure S12 .....	19
Figure S13 .....	21
Figure S14 .....	22
Figure S15 .....	23
Figure S16 .....	23
Figure S17 .....	24
Figure S18 .....	25
Figure S19 .....	26
Figure S20 .....	27
Figure S21 .....	28
Figure S22 .....	32
Figure S23 .....	33
Figure S24 .....	36
<b>Supplementary Tables</b> .....	<b>37</b>
Table S1. Plasmids used in this study .....	37
Table S2. Oligonucleotides used in this study .....	39
<b>Gene and Plasmid Sequences</b> .....	<b>41</b>
<b>References</b> .....	<b>56</b>

## Materials and Methods

### General

All ncAAs were purchased from Chem-Impex International, Click Chemistry Tools, 1 ClickChemistry, or Sigma-Aldrich, and used without further purification. Enzymes and reagents for molecular cloning were purchased from New England Biolabs (NEB) and Takara Bio USA. Oligonucleotide synthesis was performed by the Keck Biotechnology Resource Laboratory at Yale University. DNA sequencing services were provided by the Keck Biotechnology Resource Laboratory and Quintara Biosciences. Mass spectrometry services were provided by Bioinformatics Solutions Inc. Unless noted, antibiotics for cell cultures were used at the following concentrations: ampicillin (Amp), 100 µg/mL; spectinomycin (Spec), 50 µg/mL; chloramphenicol (Cm), 34 µg/mL; tetracycline (Tet), 12 µg/mL.

### Safety Statement

No unexpected, new, or significant hazards or risks were encountered during the course of this work.

### Plasmid Construction

For a complete list of the plasmids used in this study see Table S1. Primer sequences are given in Table S2.

*pBAD-sfGFP[2UAG]-MmtRNA<sup>Pyl</sup><sub>CUA</sub>* (pJT008) and *pBAD-sfGFP[2UAG]-MatRNA(6)<sup>Pyl</sup><sub>CUA</sub>* (pJT010): plasmids pJT008 and pJT010 were constructed as described previously.<sup>1</sup> Briefly, tRNA<sup>Pyl</sup> expression cassettes under control of an Lpp promoter were PCR-amplified from preexisting pCAM-cat[1UAG]-tRNA<sup>Pyl</sup> constructs, using primers JT27/JT28. The amplified fragments were digested with *Sph*I and cloned into *Sph*I-digested pBAD-sfGFP[2UAG] using the In-Fusion® HD Cloning Kit (Takara Bio Inc.).

*pBAD-sfGFP[1NNN]-itRNA<sup>Ty2</sup><sub>CUA</sub>*: (pJT100-pJT107): The initiating methionine codon of sfGFP was mutated to UAC, UAU, UUC, UGC, UCC, AAC, GAC, or CAC by amplifying the previously reported plasmid pJT052<sup>1</sup> with the reverse primer JT261 and forward primers JT262–JT268. The PCR products were circularized using the In-Fusion® HD Cloning Kit.

*pBAD-sfGFP[1NNN]-itRNA<sup>Ty2</sup><sub>NNN</sub>* (pJT108-pJT115): The anticodon of *itRNA<sup>Ty2</sup><sub>CUA</sub>* in plasmids pJT100-pJT107 was mutated to match the initiating codon of sfGFP[1NNN] by amplifying the plasmids with the reverse primer JT271 and the forward primers JT272–JT279. The PCR products were circularized using NEBuilder® HiFi DNA Assembly Master Mix (NEB).

*pBAD-sfGFP<sup>Opt</sup>[1UAU]-itRNA<sup>Ty2</sup><sub>AUA</sub>* (pJT117): A codon optimized variant of sfGFP in which all UAU codons were replaced with UAC (sfGFP<sup>Opt</sup>) was synthesized by Integrated DNA Technologies. The synthetic gene was amplified with primers JT292/JT293 while a recipient vector (pJT109) was amplified with primers JT290/JT291. The PCR products were assembled using NEBuilder® HiFi DNA Assembly Master Mix.

*pBAD-sfGFP<sup>Opt</sup>[1UAU-135UAG-151UAA]-itRNA<sup>Ty2</sup><sub>AUA</sub>* (pJT121): The template plasmid pJT117 was amplified with primers JT296/JT297 to introduce a Y151→UAA mutation in the sfGFP[1UAU] gene. The resulting plasmid was subsequently amplified with primers JT294/JT295 to introduce a N135→UAG mutation affording sfGFP<sup>Opt</sup>[1UAU-135UAG-151UAA].

*pBAD-sfGFP<sup>Opt</sup>[1UAU-135UAG-151UAA]-itRNA<sup>Ty2</sup><sub>AUA</sub>-MmtRNA<sup>Pyl</sup><sub>AAU</sub>* (pJT151): The plasmid pEVOL-MmtRNA<sup>Pyl</sup><sub>CUA</sub>-MmPylRS(N346A/C348A) was a gift from Professor Wenshe Liu at Texas A&M University (Addgene plasmid #127411).<sup>2</sup> The *MmtRNA<sup>Pyl</sup><sub>CUA</sub>* expression cassette was amplified from this plasmid

using the primer pair JT317/JT318. A recipient plasmid (pJT121) was simultaneously linearized with primers JT313/JT314. The purified PCR products were assembled using NEBuilder® HiFi DNA Assembly Master Mix to afford *pBAD-sfGFP<sup>Opt</sup>[1UAU-135UAG-151UAA]-itRNA<sup>Ty2</sup><sub>AUA</sub>-MmtRNA<sup>Pyl</sup><sub>CUA</sub>*. This plasmid was subsequently amplified with primers JT356/JT357 to mutate the anticodon of *MmtRNA<sup>Pyl</sup>* from CUA to UAA and to introduce a previously reported U:G→C:G mutation in the anticodon stem for improved suppression efficiency.<sup>3</sup>

*pBAD-sfGFP<sup>Opt</sup>[1UAU-135UAG-151UAA]-itRNA<sup>Ty2</sup><sub>AUA</sub>-MatRNA(6)<sup>Pyl</sup><sub>CUA</sub>* (pJT166): The *MatRNA(6)<sup>Pyl</sup><sub>CUA</sub>* expression cassette under control of a the *proK* promoter was PCR-amplified from plasmid pJT159 using primers JT396/JT397. The recipient plasmid (pJT121) was simultaneously linearized with primers JT394/JT395. The purified PCR products were then assembled with NEBuilder® HiFi DNA Assembly Master Mix.

*pBAD-sfGFP<sup>Opt</sup>[1UAU-135UAG]-itRNA<sup>Ty2</sup><sub>AUA</sub>-MatRNA(6)<sup>Pyl</sup><sub>CUA</sub>-MmtRNA<sup>Pyl</sup><sub>UUA</sub>* (pJT171): Plasmid pJT167 was constructed in the same manner as pJT166 but using pJT151 as the recipient plasmid. pJT167 was amplified with primers JT362/JT363 to revert the 151UAA mutation, affording pJT171.

*pBAD-sfGFP<sup>Opt</sup>[1UAU-151UAA]-itRNA<sup>Ty2</sup><sub>AUA</sub>-MatRNA(6)<sup>Pyl</sup><sub>CUA</sub>-MmtRNA<sup>Pyl</sup><sub>UUA</sub>* (pJT172): Like pJT171, pJT172 was constructed using pJT167 as a template. pJT167 was amplified with primers JT360/JT361 to revert the 135UAG mutation affording pJT172.

*pBAD-sfGFP<sup>Opt</sup>[1UAG]-itRNA<sup>Ty2</sup><sub>AUA</sub>* (pJT122): The synthetic *sfGFP<sup>Opt</sup>* gene was amplified with primers JT293/JT302. The recipient vector (pJT052) was simultaneously amplified with primers JT290/JT291. The PCR products were then assembled using NEBuilder® HiFi DNA Assembly Master Mix.

*pBAD-sfGFP<sup>Opt</sup>[2UAG]-itRNA<sup>Ty2</sup><sub>AUA</sub>* (pJT123): The plasmid pJT117 was amplified with primers JT300/JT301 to revert the 1UAU mutation and introduce an 2UAG mutation. The PCR product was then assembled using NEBuilder® HiFi DNA Assembly Master Mix.

*pBAD-sfGFP<sup>Opt</sup>[2UAA]-itRNA<sup>Ty2</sup><sub>AUA</sub>* (pJT124): The plasmid pJT117 was amplified with primers JT298/JT299 to revert the 1UAU mutation and simultaneously introduce an 2UAA mutation. The PCR product was then assembled using NEBuilder® HiFi DNA Assembly Master Mix.

*pULTRA-MmPylRS-MmtRNA<sup>Pyl</sup><sub>UUA</sub>* (pJT156): Wildtype *MmPylRS* was amplified from a preexisting pEVOL plasmid using primers JT348/JT349. A previously reported recipient plasmid (pJT079) was simultaneously linearized with primers JT347/JT169.<sup>1</sup> The purified PCR products were then assembled with NEBuilder® HiFi DNA Assembly Master Mix to afford *pULTRA-MmPylRS-MatRNA<sup>Pyl</sup><sub>UUA</sub>*. The *MatRNA<sup>Pyl</sup><sub>UUA</sub>* in this plasmid was replaced with *MmtRNA<sup>Pyl</sup><sub>UUA</sub>* by amplifying the plasmid with primers JT356/JT357.

*pULTRA-MaPylRS-MatRNA(6)<sup>Pyl</sup><sub>CUA</sub>* (pJT173): The anticodon of *MatRNA(6)<sup>Pyl</sup><sub>UUA</sub>* in the previously reporter plasmid pJT079<sup>1</sup> was mutated to CUA by amplifying the plasmid with primers JT355/JT176 to afford pJT173.

*pSTART-AzFRS.2.t1-MaPylRS(N166S)-MatRNA(6)<sup>Pyl</sup><sub>CUA</sub>* (pJT159 and pJT160): The plasmid pEVOL-AzFRS.2.t1-*MjtRNA<sup>Tyr</sup><sub>CUA</sub>* was a kind gift from Professor Farren Isaacs at Yale University (Addgene plasmid #73546). To clone *MaPylRS* into the preexisting *glnS* promoter, this plasmid was amplified with primers JT351/JT352. Simultaneously, *MaPylRS(N166S)* was amplified from pJT138 using primers JT353/354. The two PCR products were then assembled using NEBuilder® HiFi DNA Assembly Master

Mix. *MjtRNA*<sup>Tyr</sup><sub>CUA</sub> was then replaced with *MatRNA*(6)<sup>Pyl</sup><sub>CUA</sub> by amplifying the resultant plasmid with JT176/JT355 to afford pEVOL-AzFRS.2.t1-*MaPylRS*(N166S)-*MatRNA*(6)<sup>Pyl</sup><sub>CUA</sub>. The *glnS*-*MaPylRS*(N166S)-*proK*-*MatRNA*(6)<sup>Pyl</sup><sub>CUA</sub>-*Cm*<sup>R</sup> portion of this plasmid was amplified with primers JT372/JT373 and cloned into pMW-AzFRS.2.t1 (linearized with primers JT370/371) to afford pJT159. To change the *glnS* promoter for *MaPylRS*(N166S) to the stronger lac promoter, pJT159 was amplified with primers JT386/JT387 and *lac*-*MaPylRS*(N166S) was simultaneously amplified from pJT138 using primers JT388/389. The PCR products were assembled with NEBuilder® HiFi DNA Assembly Master Mix to afford pJT160.

*pSTART*-*AzFRS.2.t1* (pJT174): To remove *MaPylRS*(N166S)-*MatRNA*(6)<sup>Pyl</sup><sub>CUA</sub> from pJT159 the plasmid was amplified with primers JT398/JT399 and assembled with NEBuilder® HiFi DNA Assembly Master Mix to afford pJT174.

### Protein Expression and Purification

All sfGFP mutants were expressed in the *E. coli* strain DH10BΔ*metZ*WV. For a typical experiment, freshly transformed colonies of DH10BΔ*metZ*WV containing the appropriate plasmids (Table S1) were grown overnight in 2xYT media supplemented with antibiotics. The following day, overnight cultures were diluted 1:100 (1:20 for three-plasmid systems) in chemically defined media<sup>1</sup> and grown at 37°C to an OD<sub>600</sub> of 0.25-0.5, at which point protein expression was induced with the addition of 1 mM IPTG, 0.2% arabinose, and 2 mM of the indicated ncAA(s). Cells were cultured for an additional 18-20 hours and then harvested by centrifugation.

Cells were lysed by resuspending pellets in BugBuster® 10x Protein Extraction Reagent (Millipore-Sigma) that was diluted in lysis buffer (50 mM Tris pH 8.0, 500 mM NaCl, 10 mM imidazole) and supplemented with 25 U/mL Benzonase® Nuclease (Sigma). Following lysis, the solution was clarified by centrifugation (10,000 × *g*, 30 min) and proteins were purified in a gravity flow column using TALON® Metal Affinity Resin (Clontech). The resin was washed with lysis buffer and bound proteins were eluted with elution buffer (50 mM Tris pH 8.0, 100 mM NaCl, 250 mM imidazole). Purified proteins were concentrated, and the buffer was exchanged to 25 mM sodium phosphate pH 7.4, 25 mM NaCl using Amicon® Ultra Centrifugal Filters (10 kDa NMWL). Final protein concentrations were estimated using the absorbance at 280 nm.

### In vivo sfGFP Reporter Assay

For a typical experiment, freshly transformed colonies of *E. coli* DH10B or DH10BΔ*metZ*WV (as indicated), containing the appropriate plasmids (Table S1), were isolated and grown to saturation in 2xYT supplemented with antibiotics. Saturated cultures (5 μL) were used to inoculate 150 μL of chemically defined media<sup>1</sup>, supplemented with antibiotics, 0.1 mM IPTG, 0.2% arabinose, and 2 mM of the indicated ncAA(s), in black, clear bottom, 96-well plates. Cultures were grown in a BioTek Synergy microplate reader at 37°C with 12 min of continuous shaking every 15 min. Fluorescence intensity ( $\lambda_{\text{ex}} = 485 \text{ nm}$ ,  $\lambda_{\text{em}} = 528 \text{ nm}$ ) and OD<sub>600</sub> were measured every 15 min for the duration of the experiment. Unless noted otherwise, data are reported as the fluorescence intensity divided by the OD<sub>600</sub> at the 18-hour timepoint.

### In vitro tRNA Aminoacylation

*Preparation of tRNA Transcripts:* The genes for *EctRNA*<sup>Tyr</sup> and *tRNA*<sup>Ty2</sup><sub>AUA</sub> were cloned into pUC18 under the T7 promoter using NEBuilder® HiFi cloning. Briefly, primers 418.F and 418.R were used to amplify pUC18 for cloning of *tRNA*<sup>Ty2</sup><sub>AUA</sub>. 417.F and 417.R primers, containing the *tRNA*<sup>Ty2</sup><sub>AUA</sub> gene were annealed prior to ligation with linearized pUC18. Similarly, primers 407.F and 407.R were used to amplify pUC18 for *EctRNA*<sup>Tyr</sup> cloning, while 413.F and 413.R primers (containing the *EctRNA*<sup>Tyr</sup> gene) were annealed before ligation into pUC18. *In vitro* transcription of *EctRNA*<sup>Tyr</sup> and *tRNA*<sup>Ty2</sup><sub>AUA</sub> was carried out using DNA fragments from the pUC18 constructs amplified with the pUC18\_un primer together with the

436 and 437 primers for *tRNA*<sup>Ty<sub>2</sub><sub>AUA</sub></sup> and *EctRNA*<sup>Tyr</sup>, respectively. T7 RNA polymerase was purified following a previously published protocol.<sup>4</sup> The *in vitro* run-off transcription was performed in 40 mM Tris-HCl pH 8, 1 mM spermidine, 0.01% Triton X-100, 0.005 mg/mL BSA, 10 mM DTT, 20 mM MgCl<sub>2</sub>, 3 mM NTPs, and 10 µg DNA template for 7 h at 37°C.

*Preparation of E. coli TyrRS:* His-tagged *E. coli* TyrRS (*EcTyrRS*) was purified using an *E. coli* strain from the ASKA collection harboring the *EcTyrRS* expression plasmid.<sup>5</sup> Cells were grown to an OD<sub>600</sub> of 0.6 followed by induction of *EcTyrRS* expression with 1 mM IPTG for 4 h at 37°C. Cells were collected by centrifugation and resuspended in buffer containing 50 mM Tris pH 8, 300 mM NaCl, and protease inhibitor tablets (Roche). Cell lysis was carried out using lysozyme followed by sonication. Cell lysate was cleared by centrifugation at 19000 × *g* for 50 min at 4°C. The His-tagged protein was isolated using TALON® Metal Affinity Resin (Clontech) and eluted using varying concentration of imidazole. The purified protein was concentrated and stored at -20°C in buffer containing 12.5 mM HEPES pH 7.3, 75 mM NaCl, and 40% glycerol. Protein concentration was determined using the Bradford assay.<sup>6</sup>

*Aminoacylation Reactions:* Aminoacylation reactions were performed at 37°C in a solution containing 50 mM HEPES pH 7.3, 4 mM ATP, 10 mM MgCl<sub>2</sub>, 3 mM KCl, 2.5 µM [<sup>3</sup>H]-tyrosine (PerkinElmer), 5 µM tRNA, and 0.5 µM *EcTyrRS*. At indicated time points, 10 µL of reaction mixture was quenched on a filter pad (Whatman 3MM) pre-soaked with 5% TCA. Pads were washed three times with 5% TCA followed by a final wash with absolute ethanol. Pads were air-dried and radioactivity was measured using a scintillation counter. A reaction in the absence of tRNA was used to measure the background level of Tyr binding to the filter in the presence of *EcTyrRS*. All data points are the average of at least three independent experiments with the standard deviation indicated. Data were plotted using the GraphPad Prism software.

### **MaPyIRS N166/V168 Library Screening**

The two-site *MaPyIRS* library was prepared by amplifying the plasmid pJT065 (containing the wildtype *MaPyIRS* gene) with primers JT269/JT270. The PCR product was digested with *DpnI* and then circularized using NEBuilder® HiFi DNA Assembly Master Mix. The cloned product was then used to transform *E. coli* DH10B containing the selection plasmid pCAM-Ma (Table S1). Transformed cells were recovered at 37°C for 1 hour and then plated on chemically defined agar plates<sup>1</sup> supplemented with Spec, Tet, 50 µg/mL Cm, 1 mM IPTG, and 1 mM mIF or oMeF. Plates were incubated at 37°C for ~20 hours and then surviving clones were screened for ncAA recognition by replating on plates with and without an ncAA (Figure S15).

### **Protein Labeling**

*3-azido-7-hydroxycoumarin and Fluor 488-alkyne Labeling:* To 92 µL of reaction buffer (25 mM sodium phosphate pH 7.4, 25 mM NaCl) was added CuSO<sub>4</sub> (2 µL, 5 mM) and BTAA (2 µL, 10 mM in DMSO, Click Chemistry Tools). The solution was mixed and then added to a sample of protein (100 µL, 20 µM) in reaction buffer. To the resulting mixture was added, sequentially, 3-azido-7-hydroxycoumarin (2 µL, 10 mM in DMSO, Santa Cruz Biotechnology) or fluor 488-alkyne (2 µL, 10 mM in DMSO, Sigma-Aldrich) and sodium ascorbate (2 µL, 250 mM). The resulting solution was incubated at room temperature for 2 hours. After the reaction, excess dye and reagents were removed by three rounds of 5-fold dilution in reaction buffer, followed by concentration using Amicon® Ultra Centrifugal Filters (3 kDa NMWL). Labeled proteins were resolved by SDS-PAGE and in-gel fluorescence images were captured using a Bio-Rad ChemiDoc™ Imager using the preset filter. After fluorescence imaging, gels were stained with Coomassie blue, de-stained in water:methanol:acetic acid, and imaged using the Coomassie blue setting of the same imager.

*HiLyte™ Fluor 488-hydroxylamine Labeling*: Protein samples (25  $\mu$ L, 40  $\mu$ M in 25 mM sodium phosphate pH 7.4, 25 mM NaCl) were diluted with 75  $\mu$ L of a low pH buffer (100 mM potassium phosphate pH 4.5, 250 mM NaCl) resulting in a final solution pH of  $\sim$ 5.8. To the diluted samples was added HiLyte™ Fluor 488-hydroxylamine (2  $\mu$ L, 25 mM in DMSO, AnaSpec Inc.). The solution was mixed and then incubated at 25°C for 18 hours. After the reaction, excess dye was removed by three rounds of 5-fold dilution in reaction buffer, followed by concentration using Amicon® Ultra Centrifugal Filters (3 kDa NMWL). Labeled proteins were resolved by SDS-PAGE and in-gel fluorescence images were captured using a Bio-Rad ChemiDoc™ Imager using the Alexa 488 preset filter. After fluorescence imaging, gels were stained with Coomassie blue, de-stained in water:methanol:acetic acid, and imaged using the Coomassie blue setting of the same imager.

### **Proteome Labeling**

DH10B $\Delta$ *metZ*WV were co-transformed with a pMW plasmid encoding AzFRS.2.t1 and a pBAD plasmid encoding *tRNA*<sup>Ty2</sup><sub>AUA</sub>, *tRNA*<sup>Ty2</sup><sub>CUA</sub>, or no *tRNA*. Cells were grown overnight in 2xYT media supplemented with antibiotics and overnight cultures were used to inoculate 10 mL of defined media<sup>1</sup> supplemented with antibiotics. Cells were grown at 37°C to OD<sub>600</sub>  $\sim$ 0.3 at which point cultures were supplemented with 0.1 mM IPTG and 2 mM pAzF. Cells were grown an additional  $\sim$ 16 hours and then harvested by centrifugation. Cells were lysed by resuspending pellets in BugBuster® 10x Protein Extraction Reagent (Millipore-Sigma), diluted in PBS and supplemented with 25 U/mL Benzonase® Nuclease (Sigma) and cComplete™ EDTA-free protease inhibitor cocktail (ThermoFisher). Total protein concentration was estimated using the Pierce™ BCA protein assay kit and lysates were adjusted to  $\sim$ 1 mg/mL by diluting with lysis buffer. Diluted lysates (90  $\mu$ L) were labeled by adding, sequentially, freshly prepared Cu<sup>I</sup>-Ligand mixture (10  $\mu$ L, 10 mM CuSO<sub>4</sub> and 1 mM BTAA in 10% DMSO), *Fluor 488-alkyne* (1  $\mu$ L, 10 mM in DMSO), and tris(2-carboxyethyl)phosphine (1  $\mu$ L, 100 mM in water). The reaction was incubated at room temperature for 1 hour and then excess dye and reagents were removed by three rounds of 5-fold dilution in PBS followed by concentration using Amicon® Ultra Centrifugal Filters (3 kDa NMWL). Labeled lysates were resolved by SDS-PAGE and in-gel fluorescence images were captured using a Bio-Rad ChemiDoc™ Imager using the Alexa 488 preset filter. After fluorescence imaging, gels were stained with Coomassie blue, de-stained in water:methanol:acetic acid, and imaged using the Coomassie blue setting of the same imager.

### **Cell Growth Analysis**

DH10B $\Delta$ *metZ*WV were co-transformed with a pMW plasmid encoding AzFRS.2.t1 and a pBAD plasmid encoding *tRNA*<sup>Ty2</sup><sub>AUA</sub>, *tRNA*<sup>Ty2</sup><sub>CUA</sub>, or no *tRNA*. Freshly transformed colonies were isolated and grown overnight in 2xYT media supplemented with antibiotics. Overnight cultures were diluted to OD<sub>600</sub>  $\sim$ 0.4 and 2  $\mu$ L of the diluted culture was used to inoculate 150  $\mu$ L of defined media<sup>1</sup> supplemented with antibiotics, 0.1 mM IPTG, and 2 mM pMeF, in a black, clear bottom 96-well plate. Cultures were incubated for an additional 20 hours in a BioTek Synergy microplate reader at 37°C with 12 min of continuous shaking every 15 min. The OD<sub>600</sub> was measured every 15 min for the duration of the experiment. Instantaneous doubling times were calculated for individual growth curves (OD<sub>600</sub> vs. time) using the linear portion of the exponential growth phase as described previously.<sup>7</sup> Carrying capacities were determined by fitting a logistic growth model to conglomerate growth curves using GraphPad Prism.

### **Mass Spectroscopy**


The mass spectroscopy data shown in Figure 1E were collected exactly as reported previously.<sup>1</sup> All other LC-MS and MS/MS were performed by Bioinformatics Solutions Inc. in Waterloo, Ontario, Canada as follows:

*Intact Protein LC-MS:* LC-MS analysis of intact proteins was performed on a Thermo Scientific Orbitrap Fusion Lumos Tribrid mass spectrometer equipped with a heated electrospray ionization source with a Thermo Fisher Ultimate 3000 RSLCnano HPLC System. Proteins were analyzed on a MAbPac RP analytical column (4  $\mu\text{m}$ , 3.0  $\times$  50 mm, 70°C, ThermoFisher) using a mobile phase consisting of water/acetonitrile in 0.1% formic acid. Proteins were separated at a rate of 500  $\mu\text{L}/\text{min}$  under the following gradient: 0–11 min, 10–45% acetonitrile; 11–13 min, 45–95% acetonitrile; 13–15 min, 95% acetonitrile; 15–17 min, 20–10% acetonitrile; 17–20 min, 10% acetonitrile. Data were collected using full scans at 15000 resolution in the orbitrap over an  $m/z$  range of 700–2200 in positive ion mode. The maximum injection time was limited to 50 ms, with an AGC target of  $4e6$ . Ten micro scans were employed with the RF lens set to 45%. 15 V of insource CID was applied.


*LC-MS/MS:* Reduced protein samples were alkylated with iodoacetamide prior to digestion with trypsin or chymotrypsin. LC-MS/MS analysis was performed on a Thermo Scientific Orbitrap Fusion Lumos Tribrid mass spectrometer, equipped with a nanospray ionization source, in positive ion mode, and a Thermo Fisher Ultimate 3000 RSLCnano HPLC System. Digested proteins were loaded on a PepMap™ 100 C18 trap column (5  $\mu\text{m}$ , 60°C, ThermoFisher) with a flow of 30  $\mu\text{L}/\text{min}$ . Peptides were eluted at a rate of 0.2  $\mu\text{L}/\text{min}$  and separated on a ReproSil C18 analytical column (1.9  $\mu\text{m}$ , PepSep) using a water/acetonitrile mobile phase, in 0.1% formic acid, and over the following gradient: 0–45 min, 4–35% acetonitrile; 45–55 min, 90% acetonitrile; 55–60 min, 4% acetonitrile. Data were collected using data-dependent mode with a cycle time of 3 seconds. MS1 scan was performed in orbitrap with an  $m/z$  range of 400–1600 and at a resolution of 120000  $m/z$ . Maximum injection time was limited to 50 ms with an AGC target of  $4e5$ . RF lens was set to 30%. Isolation for MS2 scans was performed in the quadrupole, with an isolation window of 0.7. MS2 scans were done in the linear ion trap at turbo scan rate, with a maximum injection time of 35 ms and AGC target at  $1e4$ . CID was used for generating MS2 spectrum, as fixed normalized collision energy of 30% and activation time at 10 ms.

*Data Analysis:* Raw data files were processed using PEAKS XPro (v10.6, Bioinformatics Solutions Inc., Ontario, Canada). The data were searched against a custom database containing sfGFP variants with alanine substitutions where ncAA residues are inserted, in conjunction with the *E. coli* K12 Uniprot reviewed database. Parent mass tolerance was set to 10 ppm, with fragment mass tolerance of 0.6 Da. Semi-specific cleavage with trypsin or chymotrypsin was selected with a maximum of 3 missed cleavages. Fixed modifications of carbamidomethylation (57.02 Da) on cysteine residues were specified. Variable modifications of deamination (0.98 Da) on asparagine and glutamine, as well as oxidation (15.99 Da) on methionine were specified. In addition, variable modifications at alanine residues of +118.05 Da, +139.07 Da, and +201.94 Da were set for detecting insertion of pAcF, PrK, and mIF, respectively. Only peptides above a  $-10\log P$  score of 22.2 and a 1% FDR were used from the PEAKS database search.







**Figure S1. Background expression of sfGFP[1NNN] without co-expression of mutant initiator tRNA.** sfGFP expression was monitored in DH10B $\Delta$ metZ $\Delta$ WV cells expressing pCNFRS and sfGFP[1NNN]. Endogenous *E. coli* tRNAs cannot initiate translation at UAG or any of the tested sense codons. sfGFP[1UAG] and sfGFP[1UUC] afforded the highest level of background expression. Cells were grown in defined media supplemented with 0.1 mM IPTG, 0.2% arabinose, and 2 mM pMeF. Data are displayed as the mean  $\pm$  SEM of three biological replicates.




**Figure S2. Expression of sfGFP initiating at AUG, UAG, and UAU.** sfGFP expression was monitored in DH10B $\Delta$ metZ $\Delta$ WV cells expressing AzFRS.2.t1 and either wildtype sfGFP, sfGFP[1UAG] and tRNA<sup>Ty2</sup><sub>CUA</sub>, or sfGFP[1UAU] and tRNA<sup>Ty2</sup><sub>AUA</sub>. Cells were grown in defined media<sup>1</sup> supplemented with 0.1 mM IPTG, 0.2% arabinose, and 2 mM pMeF. Data are displayed as the mean  $\pm$  SEM of six biological replicates.



**Figure S3. A comparison of sfGFP[1UAU] expression in wildtype *E. coli* DH10B and in DH10B $\Delta metZWW$ .** Initiation at UAU is more efficient in DH10B $\Delta metZWW$ . Cells were grown in defined media<sup>1</sup> supplemented with 0.1 mM IPTG, 0.2% arabinose, and  $\pm$  2 mM pMeF. Data were collected 16 hours after induction and are displayed as the mean  $\pm$  SEM of three biological replicates.




**Figure S4. Extended data for Figure 2.** Uncropped gel images for Figure 2D (A) and Figure 2G (B).




**Figure S5. LC-MS of sfGFP[1UAU] expressed with pIF.** Major peaks correspond to sfGFP with pIF incorporated at the initiating position (sfGFP-1pIF; theoretical mass = 27898 Da) and *N*-formyl-sfGFP-1pIF (theoretical mass = 27926 Da).







**Figure S7. Proteome labeling of *E. coli* DH10BΔ*metZ*WV cells expressing *tRNA*<sup>Ty2</sup><sub>AUA</sub>.** Cells expressing AzFRS.2.t1 and *tRNA*<sup>Ty2</sup><sub>AUA</sub>, *tRNA*<sup>Ty2</sup><sub>CUA</sub>, or no *tRNA* were grown overnight in media containing 2 mM pAzF. The following day cells were lysed and lysates were labeled with Fluor-488 Alkyne as described in the Materials and Methods. Lysates of cells expressing *tRNA*<sup>Ty2</sup><sub>AUA</sub> were labeled to a greater degree than those from cells expressing *tRNA*<sup>Ty2</sup><sub>CUA</sub> or no *tRNA* suggesting greater integration of pAzF in the proteome. The experiment was repeated twice and representative results are shown.



**Figure S8. Growth of *E. coli* DH10BΔ*metZ*WV expressing *tRNA*<sup>Ty2</sup><sub>AUA</sub>.** (A) Growth curves for cells expressing AzFRS.2.t1 and *tRNA*<sup>Ty2</sup><sub>AUA</sub>, *tRNA*<sup>Ty2</sup><sub>CUA</sub>, or no *tRNA* (Vector). Cells were grown in defined media supplemented with 2 mM pMeF. Data are displayed as the mean ± SEM of nine biological replicates. (B) Calculated doubling time and carrying capacity for the growth curves shown in A. Values were calculated as described in the Materials and Methods.




**Figure S9. Suppression of UAU, UAG, and UAA codons by  $itRNA^{Ty2}_{AUA}$ .**  $itRNA^{Ty2}_{AUA}$  does not significantly suppress UAG or UAA. (A) Maps of the three reporter plasmids (pJT117, pJT123, and pJT124) used to measure expression of sfGFP with an initiating UAU codon or elongating UAG and UAA codons. (B) Flu/OD data for sfGFP[1UAU], sfGFP[2UAG], and sfGFP[2UAA] co-expressed with  $itRNA^{Ty2}_{AUA}$  and AzFRS.2.t1. Cells were grown in defined media<sup>1</sup> supplemented with 0.1 mM IPTG, 0.2% arabinose, and  $\pm$  2 mM pMeF. Data were collected 15 hours after induction and are displayed as the mean  $\pm$  SEM of three biological replicates. ns = not significant (paired t-test).




**Figure S10. Co-translational installation of two distinct noncanonical amino acids using UAU and UAG/UAA codons.** (A) Maps of the three-plasmid system used to install two ncAAs in response to an initiating UAU and elongating UAA. (B) Maps of the three-plasmid system used to install two ncAAs in response to an initiating UAU and elongating UAG. (C) Expression of sfGFP[1UAU-151UAA] in the presence pAcF and PrK. (D) Expression of sfGFP[1UAU-135UAG] in the presence of pAcF and PrK. Cells were grown in defined media<sup>1</sup> supplemented with 0.1 mM IPTG, 0.2% arabinose, and  $\pm$  2 mM pAcF and PrK. Data were collected 18 hours after induction and are displayed as the mean  $\pm$  SEM of three biological replicates.








**Figure S11.** (Continued on next page)




**Figure S11. MS/MS analysis of sfGFP-1pAcF-135PrK.** The spectra support the incorporation of pAcF at position 1 (A) and PrK at position 135 (B). ncAAs are abbreviated in the peptide sequence with the letter *a*.




**Figure S12.** (Continued on next page)




**Figure S12. MS/MS analysis of sfGFP-1pAcF-151PrK.** The spectra support the incorporation of pAcF at position 1 (A) and PrK at position 151 (B). ncAAs are abbreviated in the peptide sequence with the letter *a*.




**Figure S13. Extended data for Figure 3E.** Uncropped gel images for labeling of sfGFP-1pAcF-135PrK and sfGFP-1pAcF-151PrK with Fluor 488-hydroxylamine (A) and coumarin azide (B).





**Figure S14. A comparison of the substrate binding pockets of *MmPylRS* and *MaPylRS*.** Key active site residues are labeled. (A) The crystal structure of *MmPylRS* in complex with adenylated pyrrolysine and pyrophosphate (PDB: 2Q7H). The hydrogen bond between N346 and the side chain amide of pyrrolysine is shown as a solid black line. (B) The crystal structure of *MaPylRS* apoenzyme (PDB: 6EZD).



**Figure S15. *MaPyIRS* N166/V168 library screening using chloramphenicol acetyltransferase mutant *cat*[112UAG].** Following the first round of selection, surviving colonies were re-plated on media with and without the indicated ncAA. Clones that survived on chloramphenicol only in the presence of the ncAA were arbitrarily chosen for sequencing of the *MaPyIRS* gene. Identified mutants are labeled. Cells were grown on defined media agar<sup>1</sup> supplemented with 50  $\mu$ g/mL chloramphenicol, spectinomycin, tetracycline, 1 mM IPTG, and 1 mM mIF, 1 mM oMeF, or no ncAA (NA).




**Figure S16. Substrate specificities of four *MaPyIRS* mutants.** All mutants were selective for mIF. Substrate specificity was determined by measuring the expression of sfGFP[2UAG] in DH10B cells that are concurrently expressing *MatRNA*(6)<sup>PyI</sup> and the indicated *MaPyIRS* mutant. Cells were grown in defined media<sup>1</sup> supplemented with 0.1 mM IPTG, 0.2% arabinose, and 2 mM of PrK, mIF, pAcF, or no ncAA (NA). Data were collected 18 hours after induction and are displayed as the mean  $\pm$  SEM of three biological replicates.




**Figure S17. Substrate specificity of *Ma*PyIRS variant N166S.** (Top) Structures of amino acid with which we tested *Ma*PyIRS(N166S) activity. (Bottom) Expression of sfGFP[2UAG] in DH10B cells co-expressing *Ma*PyIRS(N166S) and *Mat*RNA(6)<sup>Pyl</sup>. Cells were grown in defined media supplemented with 0.1 mM IPTG, 0.2% arabinose, and 2 mM of the indicated amino acid. Data were collected 18 hours after induction and are displayed as the mean  $\pm$  SEM of at least three biological replicates. NA = not added.






**Figure S18. Substrate specificities of *MaPyIRS(N166S)* and *AzFRS.2.t1*.** *MaPyIRS(N166S)* is selective for *ortho*- and *meta*-substituted phenylalanine derivatives while *AzFRS.2.t1* is selective for *para*-substituted phenylalanine. (Top) Structures of amino acids with which we tested *MaPyIRS(N166S)* and *AzFRS.2.t1* activity. (Bottom) Expression of sfGFP[2UAG] in DH10B cells co-expressing *MaPyIRS(N166S)* and *MatRNA(6)<sup>Pyl</sup>* or *AzFRS.2.t1* and *tRNA<sup>Ty2</sup>*. Cells were grown in defined media supplemented with 0.1 mM IPTG, 0.2% arabinose, and 2 mM of the indicated amino acid. Data were collected 18 hours after induction and are displayed as the mean  $\pm$  SEM of three biological replicates.




**Figure S19. Optimizing triple ncAA incorporation.** (A) Maps of the three-plasmid system used to simultaneously install three distinct ncAAs. Cells were co-transformed with one of three reporter plasmids (Reporters 1–3) and two accessory plasmids (pJT156 and either pJT159 or pJT160). Optimized expression was achieved in cells transformed with Reporter 3, pJT156, and pJT159. (B) Optimizing pyrrolysine tRNA expression. Adding the *MmtRNA*<sup>Pyl<sub>UUA</sub></sup> or *MatRNA(6)*<sup>Pyl</sup> gene to the reporter plasmid significantly improved protein yield; however, when Reporter 2 was used, excess *MmtRNA*<sup>Pyl<sub>UUA</sub></sup> suppressed both UAA and UAG (see Figure S20). Correct ncAA incorporation was achieved with Reporter 3. Data were collected 24 hours after induction and are displayed as the mean  $\pm$  SEM of two biological replicates. (C) Optimizing *MaPylRS(N166S)* expression. The reporter gene sfGFP[1UAU-135UAG-151UAA] was expressed from Reporter 1 or Reporter 2 in cells containing pJT156 and either pJT159 or pJT160. The latter is a variant of pJT159 in which *MaPylRS(N166S)* was placed under a strong lac promoter. Data were collected 24 hours after induction and are displayed as the mean  $\pm$  SEM of three biological replicates. In all cases, cells were grown in defined media<sup>1</sup> supplemented with 0.1 mM IPTG, 0.2% arabinose, and 2 mM each of BockK, mIF, and pMeF.




**Figure S20. LC-MS of sfGFP-1pAcF-135mIF-151PrK with misincorporation of PrK at position 135.**

The protein was expressed from Reporter 2 in cells containing pJT156 and pJT159 (see Figure S19). The major peak corresponds to sfGFP with all three ncAAs at the desired positions (theoretical mass = 27992 Da; observed mass = 27990 Da). The minor peak corresponds to sfGFP-1pAcF-135PrK-151PrK (theoretical mass = 27929 Da; observed mass = 27927 Da). This product results from misincorporation of PrK in response to UAG, a consequence of excess *MmtRNA*<sup>PyI</sup><sub>UUA</sub>. Misincorporation at UAG is not observed when *MatRNA*(6)<sup>PyI</sup> is in excess.



**Figure S21.** (Continued on next page)



**Figure S21.** (Continued on next page)






Figure S21. (Continued on next page)




**Figure S21. MS/MS analysis of sfGFP-1pAcF-135mIF-151PrK with misincorporation of PrK at position 135.** The spectra support incorporation of pAcF at position 1 (A), mIF at position 135 (B), PrK at position 135 (C) and PrK at position 151 (D). For each spectrum, the position of the nCAA is indicated by the letter *a*.



**Figure S22. Protein coverage map of sfGFP-1pAcF-135mIF-151PrK with misincorporation of PrK at position 135.** The map shows all peptides containing mIF and PrK that were identified during MS/MS analysis. A mixture of mIF and PrK is seen at position 135, whereas, only PrK was observed at position 151.





**Figure S23.** (Continued on next page)






Figure S23. (Continued on next page)



**Figure S23. MS/MS analysis of sfGFP-1pAcF-135mIF-151PrK.** The spectra support incorporation of pAcF at position 1 (A), mIF at position 135 (B), and PrK at position 151 (C). For each spectrum, the position of the nCAA is indicated by the letter a.



**Supplementary Figure 24. Extended data for Figure 5D.** Uncropped gel images for labeling of sfGFP-1pAcF-135mAzF-151PrK with Fluor 488-hydroxylamine (A), Fluor 488-alkyne (B), and coumarin azide (C). Coomassie stained gels are shown on the left, in-gel fluorescence images are shown on the right.

## Supplementary Tables

**Table S1. Plasmids used in this study.**

Plasmid Name	Resistance	Origin	ORF 1		ORF2		ORF3		Figure(s)
			Prom	Gene	Prom	Gene	Prom	Gene	
<b>pCAM Backbone</b>									
pCAM-Ma	Tet	p15A	P <sub>cat</sub>	cat[112UAG]	P <sub>Lpp</sub>	<i>MatRNA(6)<sup>Pyl</sup><sub>CUA</sub></i>	-	-	4D, S11
<b>pBAD Backbone</b>									
pJT008	Amp	pBR322	P <sub>BAD</sub>	sfGFP[2UAG]	P <sub>Lpp</sub>	<i>MmrRNA<sup>Pyl</sup><sub>CUA</sub></i>	-	-	4B
pJT010	Amp	pBR322	P <sub>BAD</sub>	sfGFP[2UAG]	P <sub>Lpp</sub>	<i>MatRNA(6)<sup>Pyl</sup><sub>CUA</sub></i>	-	-	4C, S12-14
pJT052	Amp	pBR322	P <sub>BAD</sub>	sfGFP[1UAG]	P <sub>Lpp</sub>	<i>iRNA<sup>Ty2</sup><sub>CUA</sub></i>	-	-	2B, 2C
pJT055	Amp	pBR322	P <sub>BAD</sub>	sfGFP[2UAG]	P <sub>Lpp</sub>	<i>iRNA<sup>Ty2</sup><sub>CUA</sub></i>	-	-	4A, S14
pJT100- pJT107 <sup>a</sup>	Amp	pBR322	P <sub>BAD</sub>	sfGFP[1NNN]	P <sub>Lpp</sub>	<i>iRNA<sup>Ty2</sup><sub>CUA</sub></i>	-	-	2B
pJT108- pJT115 <sup>b</sup>	Amp	pBR322	P <sub>BAD</sub>	sfGFP[1NNN]	P <sub>Lpp</sub>	<i>iRNA<sup>Ty2</sup><sub>NNN</sub></i>	-	-	2C-E, S2A, S3-4
pJT117	Amp	pBR322	P <sub>BAD</sub>	sfGFP <sup>Opt</sup> [1UAU]	P <sub>Lpp</sub>	<i>iRNA<sup>Ty2</sup><sub>AUA</sub></i>	-	-	2G, S1, S2B, S5
pJT121	Amp	pBR322	P <sub>BAD</sub>	sfGFP <sup>Opt</sup> [1UAU, 135UAG, 151UAA]	P <sub>Lpp</sub>	<i>iRNA<sup>Ty2</sup><sub>AUA</sub></i>	-	-	S15A-C
pJT123	Amp	pBR322	P <sub>BAD</sub>	sfGFP <sup>Opt</sup> [2UAG]	P <sub>Lpp</sub>	<i>iRNA<sup>Ty2</sup><sub>AUA</sub></i>	-	-	S5
pJT124	Amp	pBR322	P <sub>BAD</sub>	sfGFP <sup>Opt</sup> [2UAA]	P <sub>Lpp</sub>	<i>iRNA<sup>Ty2</sup><sub>AUA</sub></i>	-	-	S5
pJT151	Amp	pBR322	P <sub>BAD</sub>	sfGFP <sup>Opt</sup> [1UAU, 135UAG, 151UAA]	P <sub>Lpp</sub>	<i>iRNA<sup>Ty2</sup><sub>AUA</sub></i>	P <sub>ProK</sub>	<i>MmrRNA<sup>Pyl</sup><sub>UUA</sub></i>	S15A-C, S16-18
pJT166	Amp	pBR322	P <sub>BAD</sub>	sfGFP <sup>Opt</sup> [1UAU, 135UAG, 151UAA]	P <sub>Lpp</sub>	<i>iRNA<sup>Ty2</sup><sub>AUA</sub></i>	P <sub>ProK</sub>	<i>MatRNA(6)<sup>Pyl</sup><sub>CUA</sub></i>	5A-D, S15A-B, S19-20
pJT171 <sup>c</sup>	Amp	pBR322	P <sub>BAD</sub>	sfGFP <sup>Opt</sup> [1UAU, 151UAA]	P <sub>Lpp</sub>	<i>iRNA<sup>Ty2</sup><sub>AUA</sub></i>	P <sub>ProK</sub>	<i>MmrRNA<sup>Pyl</sup><sub>UUA</sub></i>	3A, 3C, 3E, S6A, S6C, S8-9
pJT172 <sup>d</sup>	Amp	pBR322	P <sub>BAD</sub>	sfGFP <sup>Opt</sup> [1UAU, 135UAG]	P <sub>Lpp</sub>	<i>iRNA<sup>Ty2</sup><sub>AUA</sub></i>	P <sub>ProK</sub>	<i>MatRNA(6)<sup>Pyl</sup><sub>CUA</sub></i>	3B, 3D, 3E, S6B, S6D, S7, S9
<b>pMW Backbone</b>									
pJT048	Spec	SC101	P <sub>Lac</sub>	pCNFRS	-	-	-	-	2B-E, S2A, S3-4
pJT057	Spec	SC101	P <sub>Lac</sub>	AzFRS.2.t1	-	-	-	-	2G, 4A, S1, S2B, S5, S14
pJT064	Spec	SC101	P <sub>Lac</sub>	<i>MmPylIRS</i>	-	-	-	-	4B
pJT065	Spec	SC101	P <sub>Lac</sub>	<i>MaPylIRS</i>	-	-	-	-	4C
pJT131	Spec	SC101	P <sub>Lac</sub>	<i>MmPylIRS(N346A, C348A)</i>	-	-	-	-	4B
pJT135	Spec	SC101	P <sub>Lac</sub>	<i>MaPylIRS(N166V)</i>	-	-	-	-	S12
pJT136	Spec	SC101	P <sub>Lac</sub>	<i>MaPylIRS(N166S, V168I)</i>	-	-	-	-	S12
pJT137	Spec	SC101	P <sub>Lac</sub>	<i>MaPylIRS(N166G, V168I)</i>	-	-	-	-	S12
pJT138	Spec	SC101	P <sub>Lac</sub>	<i>MaPylIRS(N166S)</i>	-	-	-	-	4C, S12-14

pULTRA Backbone										
pJT156	Spec	CloDF13	P <sub>tac</sub>	<i>MmPylRS</i>	P <sub>proK</sub>	<i>MmtRNA</i> <sup>Pyl<sub>UUA</sub></sup>	–	–		3A, 3C, 3E, 5A-D, S6A, S6C, S8-9, S15A-C, S16-20
pJT173	Spec	CloDF13	P <sub>tac</sub>	<i>MaPylRS</i>	P <sub>proK</sub>	<i>MatRNA(6)</i> <sup>Pyl<sub>CUA</sub></sup>	–	–		3B, 3D-E, S6B, S6D, S7, S9
pSTART Backbone										
pJT159	Cm	SC101	P <sub>Lac</sub>	AzFRS.2.t1	P <sub>glnS</sub>	<i>MaPylRS(N166S)</i>	P <sub>ProK</sub>	<i>MatRNA(6)</i> <sup>Pyl<sub>CUA</sub></sup>		5A-D, S15A-C, S16-20
pJT160	Cm	SC101	P <sub>Lac</sub>	AzFRS.2.t1	P <sub>Lac</sub>	<i>MaPylRS(N166S)</i>	P <sub>ProK</sub>	<i>MatRNA(6)</i> <sup>Pyl<sub>CUA</sub></sup>		S15A, S15C
pJT174	Cm	SC101	P <sub>Lac</sub>	AzFRS.2.t1	–	–	–	–		3A-E, S6A-D, S7-9

<sup>a</sup>sfGFP variants with initiating codons UAC, UAU, UUC, UGC, UCC, AAC, GAC, and CAC.

<sup>b</sup>sfGFP variants with initiating codons UAC, UAU, UUC, UGC, UCC, AAC, GAC, and CAC and corresponding *tRNA*<sup>Ty2</sup> anticodon mutants.

<sup>c</sup>ORF4: Promoter, P<sub>ProK</sub>; Gene, *MatRNA(6)*<sup>Pyl<sub>CUA</sub></sup>

<sup>d</sup>ORF4: Promoter, P<sub>ProK</sub>; Gene, *MmtRNA*<sup>Pyl<sub>UUA</sub></sup>

**Table S2. Oligonucleotides used in this study**

Name	Sequence (5'→3')
JT27	GCGAAGGCGAAGCGGAAGCTTAAAAAATCCTTAGCTTT
JT28	GACAGGCACATTATGCTGGCGCCGCTTCTTTGA
JT169	GCGGCCGCACCTCCTTTG
JT176	TAAAACCTAGCATAGCGGGTTCGACACCCCGTCTCTCGCCAAATTCGAAAAGCCTGCTCAACG
JT261	TTTAGCTTCCTCCTGTTAGCCCA
JT262	CAGGAGGAAGCTAAATATGACAAGGGCGAAGAAGCTG
JT263	CAGGAGGAAGCTAAATTCGACAAGGGCGAAGAAGCTG
JT264	CAGGAGGAAGCTAAATGCGACAAGGGCGAAGAAGCTG
JT265	CAGGAGGAAGCTAAATCCGACAAGGGCGAAGAAGCTG
JT266	CAGGAGGAAGCTAAAAACGACAAGGGCGAAGAAGCTG
JT267	CAGGAGGAAGCTAAAGACGACAAGGGCGAAGAAGCTG
JT268	CAGGAGGAAGCTAAACACGACAAGGGCGAAGAAGCTG
JT269	CAGCATGGTAAATTCCTCCAGATGCATACCG
JT270	GAATTTACCATGCTGNNMCTGNNMGATATGGGTCCGCGTGGTG
JT271	AACCCGAAGATCGTCGGTTCAAATCCG
JT272	GACGATCTTCGGGTTTACAGCCCGACGAGCTACCA
JT273	GACGATCTTCGGGTTTATAGCCCGACGAGCTACCA
JT274	GACGATCTTCGGGTTTTAGCCCGACGAGCTACCA
JT275	GACGATCTTCGGGTTTGCAGCCCGACGAGCTACCA
JT276	GACGATCTTCGGGTTTCCAGCCCGACGAGCTACCA
JT277	GACGATCTTCGGGTTAACAGCCCGACGAGCTACCA
JT278	GACGATCTTCGGGTTGACAGCCCGACGAGCTACCA
JT279	GACGATCTTCGGGTTACAGCCCGACGAGCTACCA
JT290	CTCGAGATCTGCAGCTGGTACC
JT291	TTTAGCTTCCTCCTGTTAGCCC
JT292	CAGGAGGAAGCTAAATATAGCAAGGGCGAAGAGTTATTCA
JT293	GCTGCAGATCTCGAGTCAATGATGATGATGATGATGTGAG
JT294	AGACGGATAGATTTTAGGTCATAAGCTGGAGTAC
JT295	AAAATCTATCCGCTTCTTTGAAATCAATGCC
JT296	CAACGTATAAATTACAGCTGACAAACAGAAGAACG
JT297	GTAATTTATACGTTGTGAGAGTTAAAATTGTAC
JT298	CTAAAATGTAAAAGGGCGAAGAGTTATTACAGGG
JT299	CCTTTTACATTTTAGCTTCCTCCTGTTAGCCC
JT300	CTAAAATGTAGAAGGGCGAAGAGTTATTACAGGG
JT301	CCTTCTACATTTTAGCTTCCTCCTGTTAGCCC
JT302	CAGGAGGAAGCTAAATAGAGCAAGGGCGAAGAGTTATTCA
JT313	GCAGCAGATCAATTCGCGC
JT314	CTCGCGCTTTCGGTGATG
JT317	ACCGAAACGCGCGAGAGGCATTTTGCTATTAAGGGATTG
JT318	GAATTGATCTGCTGCGCATGCAAAAAGCCTGC
JT347	AGATTTTAGAGCCAATTAGAAAGAG
JT348	AGGAGGTGCGGCCGCATGGATAAAAAACCGCTGAATACCC
JT349	TTGGCTCTAAAATCTTCACAGGTTGGTACTAATACCATTGTAA
JT351	CTGCAGTTTCAAACGCTAAATTGCC

JT352 ATGGGATTCCTCAAAGCGTAAAC  
JT353 TTTGAGGAATCCCATATGACAGTCAAATACACCGATGCAC  
JT354 CGTTTGAAACTGCAGTCAATTGATCTTGGCACCATTCA  
JT355 CTATGCTAGGTTTTAGAGACCCGCTGGTCGCCGACCGTCCCCAATGCGGGGCGCATCTTACTG  
JT356 CTTTAAATCCGTTCCAGCCGGGTTAGATTCCCGGGGTTCCGCCAAATCGAAAAGCCTGCTCAACG  
JT357 GCTGAACGGATTTAAAGTCCGTTTCGATCTACATGATCAGGTTTCCAATGCGGGGCGCATCTTACTG  
JT360 AGACGGAAACATTTTAGGTCATAAGCTGGAGTAC  
JT361 AAAATGTTTCCGCTCTTCTTTGAAATCAATGCC  
JT362 CAACGTATACATTACAGCTGACAAACAGAAGAACG  
JT363 GTAATGTATACGTTGTGAGAGTTAAAATTGTAC  
JT370 CTCATCCTGTCTCTTGATCACTACC  
JT371 CGAACTGAGATACCTACAGCG  
JT372 AGGTATCTCAGTTCGGCTCAGTCGAAAGACTGGGCC  
JT373 AAGAGACAGGATGAGGCGAAAATGAGACGTTGATCGGC  
JT386 CTGCAGTTTCAAACGCTAAATTG  
JT387 GGACAGGCTGACAACCTGTTAG  
JT388 GTTGTGAGCCTGTCCGCAAGTGCAGCGCAACGCAA  
JT389 CGTTTGAAACTGCAGTCAATTGATCTTGGCACCATTCA  
JT394 CGGCATCCGCTTACAGACAAG  
JT395 GGAGCAGACAAGCCCGTC  
JT396 GGGCTTGTCTGCTCCGCATGCAAAAAGCCTGC  
JT397 TGTAAGCGGATGCCGAGGCATTTTGCTATTAAGGGATTG  
JT398 TTTAATATGAGCAGCTCAGGGTCGAATTTG  
JT399 GCTGCTCATATTAAGCGGGACAGGCTGAC  
407.F GAATCCTCCCCACCACCAGGCATAAGCTTGGCGTAATCA  
407.R GGCCGCTCGGGAACCCACCTATAGTGAGTCGTATTAGGATCCCCGGGTACC  
  
413.F GGTGGGGTTCCCGAGCGGCCAAAGGGAGCAGACTGTAATCTGCCGTCATCGACTTCGAAGTTTGAATCCTTCCCCACCACCA  
413.R TGGTGGTGGGGGAAGGATTCGAACCTTCGAAGTCGATGACGGCAGATTTACAGTCTGCTCCCTTTGGCCGCTCGGGAACCCACC  
  
417.F TCCTAATACGACTCACTATACGCGGGGTGGAGCAGCCTGGTAGCTCGTCGGGCTATAAACCCGAAGATCGTCGGTTCAAATCCGGC  
CCCCGCGACCATGCATAAGCTTGGCCTGGCT  
417.R AGCCAGGCCAAGCTTATGCATGGTCGCGGGGGCCGGATTTGAACCGACGATCTTCGGGTTTATAGCCCCGACGAGCTACCAGGCTG  
CTCCACCCCGCTATAGTGAGTCGTATTAGGA  
  
418.F AAATCCGGCCCCCGCACCATGCATAAGCTTGGCC  
418.R CCAGGCTGCTCCACCCCGCTATAGTGAGTCGTATTAGGATCCCCGG  
436 TGGTCGCGGGGGCCGATTG  
437 TGGTGGTGGGGGAAGG  
pUC18 CGACGTTGTAACGACGGC  
\_un

---



## DNA Sequences

a. sfGFP[1UAU]: The initiating codon is highlighted; internal UAU codons are shown in bold.

**TAT**GACAAGGGCGAAGAAGTGTTCACGGGCGTGGTGCCGATTCTGGTGGAAGTGGATGGTGATGT  
CAATGGTCACAAATTCAGCGTGCGCGGCGAAGGTGAAGGCGATGCAACCAATGGTAAACTGACGC  
TGAAGTTTATTTGCACCACGGGTAAACTGCCGTTCCGTGGCCGACCCTGGTCACCACGCTGACG  
**TAT**GGTGTTCAGTGTTTCAGTCGTTACCCGGATCACATGAAACGCCACGACTTTTTCAAGTCCGCG  
ATGCCGGAAGGT**TAT**GTCCAAGAACGTACCATCTCATTTAAAGATGACGGCACCTACAAAACGCGC  
GCCGAAGTAAATTCGAAGGTGATACGCTGGTTAACCGTATTGAACTGAAAGGCATCGATTTTAAAG  
GAAGACGGTAATATTCTGGGCCATAAACTGGAAT**TAA**ACTTCAATTTCGCACAACGTGTACATCACC  
GCAGATAAGCAGAAGAACGGTATCAAGGCTAACTTCAAGATCCGCCATAATGTGGAAGATGGCAG  
CGTTCAACTGGCCGACCACT**TAT**CAGCAAACACCCCGATTGGTGATGGCCCGGTCTGTGCTGCCG  
GACAATCATTACCTGAGCACGCAGTCTGTGCTGAGTAAAGATCCGAACGAAAAGCGTGACCACAT  
GGTCTGTGGAATTCGTGACCGCGGCCGCATCACGCACGGTATGGACGAACTGT**TAA**AGGC  
TCACATCATCATCATCATTGA

b. sfGFP<sup>Opt</sup>[1UAU]: The initiating codon is highlighted.

**TAT**AGCAAGGGCGAAGAGTTATTCACAGGGGTTGTCCCTATTCTTGTAGAATTGGATGGAGACGTA  
AACGGCCATAAATTCTCCGTACGCGGGGAAGGCGAAGGTGATGCTACAAATGGGAAATTAAGTCT  
GAAATTTATTTGCACAACCGGAAAATTACCTGTGCCTTGGCCTACTCTGGTCACGACCTTAACATAC  
GGTGTACAGTGCTTTTACGTTACCCAGATCATATGAAGCGCCACGATTTCTTCAAGAGTGCAATG  
CCTGAGGGGTACGTTCAAGAACGTACCATTTCTGTTAAGGACGATGGAACCTACAAAACCCGTGC  
AGAGGTCAAGTTTGAAGGTGACACTTTAGTTAACCGTATTGAATTAAGGGCATTGATTTCAAAGAA  
GACGGAAACATTTTAGGTCATAAGCTGGAGTACAATTTTAACTCTCACAACGTATACATTACAGCTG  
ACAAACAGAAGAACGGTATTAAGCGAATTTCAAGATCCGTACATAACGTAGAAGATGGAAGCGTAC  
AATTGGCGGATCACTACCAACAGAATACTCCTATCGGCGACGGCCCTGTGCTGCTTCCCGACAAC  
CATTACTTGTCCACTCAGAGCGTATTATCAAAGGACCCAAACGAGAAACGCGACCATATGGTGCTT  
TTAGAGTTCGTGACCGCCGCTGGCATCACCCATGGTATGGACGAGCTGTACAAGGGCTCACATCA  
TCATCATCATCATTGA

c. sfGFP<sup>Opt</sup>[1UAU-135UAG-151UAA]: The initiating codon is highlighted; internal nonsense codons are shown in bold.

**TAT**AGCAAGGGCGAAGAGTTATTCACAGGGGTTGTCCCTATTCTTGTAGAATTGGATGGAGACGTA  
AACGGCCATAAATTCTCCGTACGCGGGGAAGGCGAAGGTGATGCTACAAATGGGAAATTAAGTCT  
GAAATTTATTTGCACAACCGGAAAATTACCTGTGCCTTGGCCTACTCTGGTCACGACCTTAACATAC  
GGTGTACAGTGCTTTTACGTTACCCAGATCATATGAAGCGCCACGATTTCTTCAAGAGTGCAATG  
CCTGAGGGGTACGTTCAAGAACGTACCATTTCTGTTAAGGACGATGGAACCTACAAAACCCGTGC  
AGAGGTCAAGTTTGAAGGTGACACTTTAGTTAACCGTATTGAATTAAGGGCATTGATTTCAAAGAA  
GACGG**TAG**ATTTTAGGTCATAAGCTGGAGTACAATTTTAACTCTCACAACGT**TAA**ATTACAGCTG  
ACAAACAGAAGAACGGTATTAAGCGAATTTCAAGATCCGTACATAACGTAGAAGATGGAAGCGTAC  
AATTGGCGGATCACTACCAACAGAATACTCCTATCGGCGACGGCCCTGTGCTGCTTCCCGACAAC  
CATTACTTGTCCACTCAGAGCGTATTATCAAAGGACCCAAACGAGAAACGCGACCATATGGTGCTT  
TTAGAGTTCGTGACCGCCGCTGGCATCACCCATGGTATGGACGAGCTGTACAAGGGCTCACATCA  
TCATCATCATCATTGA

d. *t*RNA<sup>Ty2</sup><sub>AUA</sub>:

CGCGGGGTGGAGCAGCCTGGTAGCTCGTCGGGCTATAAACCCGAAGATCGTCGGTTCAAATCCG  
GCCCCGCGACCA

e. *MmtRNA*<sup>Pyl<sub>UUA</sub></sup>:

GGAAACCTGATCATGTAGATCGAACGGACTTTAAATCCGTTTCAGCCGGGTTAGATTCCCGGGGTTT  
CCGCCA

f. *MatRNA(6)*<sup>Pyl<sub>CUA</sub></sup>:

GGGGGACGGTCCGGCGACCAGCGGGTCTCTAAAACCTAGCATAGCGGGGTTTCGACACCCCGGTC  
TCTCGCCA

g. *MjTyrRS* variant pCNFRS:

ATGGACGAATTTGAAATGATAAAGAGAAACACATCTGAAATTATCAGCGAGGAAGAGTTAAGAGAG  
GTTTTAAAAAAGATGAAAAATCTGCTCTGATAGGTTTTGAACCAAGTGGTAAAATACATTTAGGGC  
ATTATCTCAAATAAAAAAGATGATTGATTTACAAAATGCTGGATTTGATATAATTATAGTTTTGGCT  
GATTTACATGCCTATTTAAACCAGAAAGGAGAGTTGGATGAGATTAGAAAAATAGGAGATTATAACA  
AAAAAGTTTTTGAAGCAATGGGGTTAAAGGCAAAATATGTTTATGGAAGTGAATGGATGCTTGATAA  
GGATTATACACTGAATGTCTATAGATTGGCTTTAAAAACTACCTTAAAAAGAGCAAGAAGGAGTATG  
GAACTTATAGCAAGAGAGGATGAAAATCCAAAGGTTGCTGAAGTTATCTATCCAATAATGCAGGTT  
AATGGTGCTCATTATCTTGGCGTTGATGTTGCAGTTGGGGGGATGGAGCAGAGAAAAATACACAT  
GTTAGCAAGGGAGCTTTTACCAAAAAAGGTTGTTTGTATTCACAACCCTGTCTTAAACGGGTTTGGAT  
GGAGAAGGAAAGATGAGTTCTTCAAAGGGGAATTTTATAGCTGTTGATGACTCTCCAGAAGAGATT  
AGGGCTAAGATAAAGAAAGCATACTGCCAGCTGGAGTTGTTGAAGGAAATCCAATAATGGAGATA  
GCTAAATACTTCCTTGAATATCCTTTAACCATAAAAAGGCCAGAAAAATTTGGTGGAGATTTGACAG  
TTAATAGCTATGAGGAGTTAGAGAGTTTATTTAAAAATAAGGAATTGCATCCAATGGATTTAAAAAT  
GCTGTAGCTGAAGAACTTATAAAGATTTTATAGAGCCAATTAGAAAGAGATTATAA

h. *MjTyrRS* variant AzFRS.2.t1:

ATGGACGAATTTGAAATGATAAAGAGAAACACATCTGAAATTATCAGCGAGGAAGAGTTAAGAGAG  
GTTTTAAAAAAGGATGAAAAATCTGCTCTGATAGGTTTTGAACCAAGTGGTAAAATACATTTAGGGC  
ATTATCTCAAATAAAAAAGATGATTGATTTACAAAATGCTGGATTTGATATAATTATATTGTTGGCT  
GATTTACACGCCTATTTAAACCAGAAAGGAGAGTTGGATGAGATTAGAAAAATAGGAGATTATAACA  
AAAAAGTTTTTGAAGCAATGGGGTTAAAGGCAAAATATGTTTATGGAAGTACTTATATGCTTGATAA  
GGATTATACACTGAATGTCTATAGATTGGCTTTAAAAACTACCTTAAAAAGGGCAAGAAGGAGTATG  
GAACTTATAGCAAGAGAGGATGAAAATCCAAAGGTTGCTGAAGTTATCTATCCAATAATGCAGGTT  
AATGGTTGCTCATTATAGGGGCGTTGATGTTGCTGTTGGAGGGATGGAGCAGAGAAAAATACACAT  
GTTAGCAAGGGAGCTTTTACCAAAAAAGGTTGTTTGTATTCACAACCCTGTCTTAAACGGGTTTGGAT  
GGAGAAGGAAAGATGAGTTCTTCAAAGGGGAATTTTATAGCTGTTGATGACTCTCCAGAAGAGATT  
AGGGCTAAGATAAAGAAAGCATACTGCCAGCTGGAGTTGTTGAAGGAAATCCAATAATGGAGATA  
GCTAAATACTTCCTTGAATATCCTTTAACCATAAAAAGGGCCAGAAAAATTTGGTGGAGATTTGACAG  
TTAATAGCTATGAGGAGTTAGAGAGTTTATTTAAAAATAAGGAATTGCATCCAATGCGCTTAAAAAA  
TGCTGTAGCTGAAGAACTTATAAAGATTTTATAGAGCCAATTAGAAAGAGATTATAA

i. *MaPylRS(N166S)*:

ATGACAGTCAAATACACCGATGCACAGATTGAGCGTCTGCGTGAATATGGTAATGGCACCTATGAA  
CAGAAAGTGTGTTGAAGATCTGGCAAGCCGTGATGCAGCATTTAGCAAAGAAATGAGCGTTGCAAG  
CACCGACAATGAGAAAAAATCAAAGGCATGATTGCAAACCCGAGCCGTCATGGTCTGACCCAGC  
TGATGAATGATATTGCAGATGCACTGGTTGCCGAAGGTTTTATTGAAGTTCGTACCCCGATTTTCAT  
CAGCAAAGATGCCCTGGCACGTATGACCATTACCGAAGATAAACCGCTGTTCAAACAGGTGTTTTG  
GATTGATGAAAAACGTGCACTGCGTCCGATGCTGGCACCGAATCTGTATAGCGTTATGCGTGATCT  
GCGCGATCATAACCGATGGTCCGGTTAAAATCTTTGAAATGGGTAGCTGCTTTGCAAAGAAAGCCA  
TAGCGGTATGCATCTGGAAGAATTTACCATGCTGTCACTGGTAGATATGGGTCCGCGTGGTGATG


CAACCGAAGTTCTGAAAACTATATTAGCGTTGTGATGAAAGCAGCAGGTCTGCCGGATTATGATC  
TGGTTCAAGAAGAAAGCGACGTCTACAAAGAAACCATTGATGTGGAAATTAACGGCCAAGAAGTTT  
GTAGCGCAGCAGTTGGTCCGCATTATCTGGATGCAGCACATGATGTGCATGAACCGTGGTCAGGT  
GCAGGTTTTGGTCTGGAACGTCTGCTGACCATTTCGTGAGAAATATAGCACCGTTAAAAAAGGTGGT  
GCGAGCATTAGCTATCTGAATGGTGCCAAGATCAATTGA

j. *MmPylRS*:

ATGGATAAAAAACCACTAAACACTCTGATATCTGCAACCGGGCTCTGGATGTCCAGGACCGGAACA  
ATTCATAAAATAAAACACCACGAAGTCTCTCGAAGCAAATCTATATTGAAATGGCATGCGGTGACC  
ACCTTGTTGTAAACAACCTCCAGGAGCAGCAGGACTGCAAGAGCGCTCAGGCACCACAAATACAGG  
AAGACCTGCAAACGCTGCAGGGTTTCGGATGAGGATCTCAATAAGTTCCTCACAAAGGCCAAACGA  
AGACCAGACAAGCGTAAAAGTCAAGGTCGTTTCTGCCCTACCAGAACGAAAAAGGCAATGCCAA  
AATCCGTTGCGAGAGCCCCGAAACCTCTTGAGAATACAGAAGCGGCACAGGCTCAACCTTCTGGA  
TCTAAATTTTACCTGCGATACCGGTTTCCACCCAAGAGTCAGTTTCTGTCCCGGCATCTGTTTCAA  
CATCAATATCAAGCATTCTACAGGAGCAACTGCATCCGCACTGGTAAAAGGGAATACGAACCCCA  
TTACATCCATGTCTGCCCTGTTTCAGGCAAGTGCCCCCGCACTTACGAAGAGCCAGACTGACAGG  
CTTGAAGTCCTGTAAACCCAAAAGATGAGATTTCCCTGAATTCCGGCAAGCCTTTCAGGGAGCTT  
GAGTCCGAATTGCTCTCTCGCAGAAAAAAGACCTGCAGCAGATCTACGCGGAAGAAAGGGAGAA  
TTATCTGGGGAAACTCGAGCGTGAAATTACCAGGTTCTTTGTGGACAGGGGTTTTCTGGAAATAAA  
ATCCCGATCCTGATCCCTCTTGAGTATATCGAAAGGATGGGCATTGATAATGATACCGAACTTTC  
AAAACAGATCTTCAGGGTTGACAAGAACTTCTGCCTGAGACCCATGCTTGCTCCAAACCTTTACAA  
CTACCTGCGCAAGCTTGACAGGGCCCTGCCTGATCCAATAAAAATTTTTGAAATAGGCCCATGCTA  
CAGAAAAGAGTCCGACGGCAAAGAACACCTCGAAGAGTTTACCATGCTGGCGTTTCGCGCAGATGG  
GATCGGGATGCACACGGGAAAATCTTGAAAGCATAATTACGGACTTCTGAACCACCTGGGAATT  
GATTTCAAGATCGTAGGCGATTCTGCATGGTCTATGGGGATACCCTTGATGTAATGCACGGAGAC  
CTGGAACCTTCTCTGCAGTAGTCGGACCCATACCGCTTGACCGGGAATGGGGTATTGATAAACC  
CTGGATAGGGGCAGGTTTTCGGGCTCGAACGCCTTCTAAAGGTTAAACACGACTTTAAAAATATCAA  
GAGAGCTGCAAGGTCCGAGTCTTACTATAACGGGATTTCTACCAACCTGTAA

k. Plasmid pJT117: The sequences of sfGFP<sup>Opt</sup>[1UAU] and tRNA<sup>Ty2</sup><sub>AUA</sub> are shown in green and indigo text, respectively. Promoter sequences are bold.

Created with SnapGene®




```

AAGAAACCAATTGTCCATATTGCATCAGACATTGCCGTCCTGCGTCTTTTACTGGCTCTTCTCGCT
AACCAAACCGGTAACCCCGCTTATTAAGCATTCTGTAACAAAGCGGGACCAAAGCCATGACAAA
AACGCGTAACAAAAGTGTCTATAATCACGGCAGAAAAGTCCACATTGATTATTTGCACGGCGTCAC
ACTTTGCTATGCCATAGCATTATTTATCCATAAGATTAGCGGATCCTACCTGACGCTTTTTATCGCAA
CTCTCTACTGTTTCTCCATACCCGTTTTTTGGGCTAACAGGAGGAAGCTAAATTATAGCAAGGGCGA
AGAGTTATTCACAGGGGTTGTCCCTATTCTTGTAAGAATTGGATGGAGACGTAACGGCCATAAAT
TCTCCGTACGCGGGGAAGGCGAAGGTGATGCTACAAATGGGAAATTAACTCTGAAATTTATTTG
CACAACCGGAAAATTACCTGTGCCTTGGCCTACTCTGGTCACGACCTTAACATACGGTGTACAG
TGCTTTTACGTTACCCAGATCATATGAAGCGCCACGATTTCTTCAAGAGTGAATGCCTGAGGG
GTACGTTCAAGAACGTACCATTTCTTTAAGGACGATGGAACCTACAAAACCCGTGCAGAGGTC
AAGTTTGAAGGTGACACTTTAGTTAACCGTATTGAATTAAGGGCATTGATTTCAAAGAAGACGG
AAACATTTTAGGTCATAAGCTGGAGTACAATTTAACTCTCACACGTATACATTACAGCTGACA
AACAGAAGAACGGTATTAAGCGAATTTCAAGATCCGTCATAACGTAGAAGATGGAAGCGTACA
ATTGGCGGATCACTACCAACAGAATACTCCTATCGGCGACGGCCCTGTGCTGCTTCCCGACAAC
CATTACTTGTCCACTCAGAGCGTATTATCAAAGGACCCAAACGAGAAACGCGACCATATGGTGC
TTTTAGAGTTCTGACCGCCGCTGGCATCACCCATGGTATGGACGAGCTGTACAAGGGCTCACA
TCATCATCATCATTGACTCGAGATCTGCAGCTGGTACCATATGGGAATTCGAAGCTTGGCTGT
TTTGGCGGATGAGAGAAGATTTTCAGCCTGATACAGATTAATCAGAACGCAGAAGCGGTCTGATA
AAACAGAATTTGCCTGGCGGCAGTAGCGCGGTGGTCCCACCTGACCCCATGCCGAACTCAGAAGT
GAAACGCCGTAGCGCCGATGGTAGTGTGGGGTCTCCCATGCGAGAGTAGGGAACTGCCAGGCA
TCAAATAAAACGAAAGGCTCAGTCGAAAGACTGGGCCTTTCGTTTTATCTGTTGTTTGTCGGTGAA
CGCTCTCCTGAGTAGGACAAATCCGCCGGGAGCGGATTTGAACGTTGCGAAGCAACGGCCCGGA
GGGTGGCGGGCAGGACGCCCGCCATAAACTGCCAGGCATCAAATTAAGCAGAAGGCCATCCTGA
CGGATGGCCTTTTTGCGTTTCTACAAACTCTTTTGTATTTTCTAAATACATTCAAATATGTATCC
GCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAGGAAGAGTATGAGTATTCAA
CATTCCGTGTGCGCCCTATTCCCTTTTTGCGGCATTTTGCTTCTCTGTTTTGCTCACCCAGAAA
    
```

CGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGAT  
CTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTT  
AAAGTTCTGCTATGTGGCGCGGTATTATCCCGTGTGACGCCGGGCAAGAGCAACTCGGTCGCCG  
CATACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGG  
CATGACAGTAAGAGAATTATGCAGTGTGTCATAACCATGAGTGATAACACTGCGGCCAACTTACT  
TCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAA  
CTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACG  
ATGCCTGTAGCAATGGCAACAACGTTGCGCAAACATTAACCTGGCGAACTACTTACTCTAGCTTCC  
CGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCT  
TCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTG  
CAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGC  
AACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACT  
GTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACCTTCATTTTTAATTTAAAAGGATCTA  
GGTGAAGATCCTTTTTGATAATCTCATGACCAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCG  
TCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTCTGCGCGTAATCTGCTGCT  
TGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTGCGGATCAAGAGCTACCAACTCTTT  
TTCCGAAGGTAACCTGGCTTCAGCAGAGCGCAGATACCAAATACTGTCCTTCTAGTGTAGCCGTAGT  
TAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAG  
TGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTGGACTCAAGACGATAGTTACCGGAT  
AAGGCGCAGCGGTCCGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACC  
TACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAA  
GGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGG  
GGGAAACGCCTGGTATCTTTATAGTCCTGTGCGGTTTTCGCCACCTCTGACTTGAGCGTCGATTTTT  
GTGATGCTCGTCAGGGGGGGCGGAGCCTATGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTC  
CTGGCCTTTTGTGGCCTTTTGTCCACATGTTCTTCTGCGTTATCCCCTGATTCTGTGGATAACC  
GTATTACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTC  
AGTGAGCGAGGAAGCGGAAGAGCGCCTGATGCGGTATTTTCTCCTTACGCATCTGTGCGGTATTT  
CACACCGCATATGGTGCACCTCTCAGTACAATCTGCTCTGATGCCGCATAGTTAAGCCAGTATACAC  
TCCGCTATCGCTACGTGACTGGGTGATGGCTGCGCCCCGACACCCGCCAACACCCCGCTGACGCG  
CCCTGACGGGCTTGTCTGCTCCCGGCATCCGCTTACAGACAAGCTGTGACCGTCTCCGGGAGCT  
GCATGTGTCAGAGGTTTTACCGTCATCACCGAAACGCGCGAGGCAGCAGATCAATTCGCGCGCG  
AAGGCGAAGCGGAAGCTTAAAAAAATCCTTAGCTTTCGCTAAGGATCTGCAGGTGACTCTAGAG  
GATCCTGGTTCGCGGGGGCCGGATTTGAACCGACGATCTTCGGGTTTATAGCCCGACGAGCTACC  
AGGCTGCTCCACCCCGCGGAATTCAGCGTTACAAGTATTACACAAAGTTTTTTATGTTGAGAATA  
TTTTTTGATGGGGCGCCACTTATTTTTGATCGTTCGCTCAAAGAAGCGGCGCCAGCATAATGTG  
CCTGTCAAATGGACGAAGCAGGGATTCTGCAAACCCTATGCTACTCCGTCAAGCCGTCAATTGTCT  
GATTCGTTACCAATTATGACAACCTTGACGGCTACATCATTCACTTTTTCTTACAACCGGCACGGAA  
CTCGCTCGGGCTGGCCCCGGTGCATTTTTTAATAACCCGCGAGAAATAGAGTTGATCGTCAAAC  
CAACATTGCGACCGACGGTGGCGATAGGCATCCGGGTGGTGCTCAAAGCAGCTTCGCCTGGCT  
GATACGTTGGTCTCGCGCCAGCTTAAGACGCTAATCCCTAACTGCTGGCGGAAAAGATGTGACA  
GACGCGACGGCGACAAGCAAACATGCTGTGCGACGCTGGCGATATCAAATTGCTGTCTGCCAG  
GTGATCGCTGATGTACTGACAAGCCTCGCGTACCCGATTATCCATCGGTGGATGGAGCGACTCGT  
TAATCGCTTCCATGCGCCGCAGTAACAATTGCTCAAGCAGATTTATCGCCAGCAGCTCCGAATAGC  
GCCCTTCCCCTTGCCCGGCGTTAATGATTTGCCCAAACAGGTGCTGAAATGCGGCTGGTGCCT  
TCATCCGGGCGAAAGAACCCCGTATTGGCAAATATTGACGGCCAGTTAAGCCATTTCATGCCAGTA  
GGCGCGCGGACGAAAGTAAACCCACTGGTGATACCATTGCGGAGCCTCCGGATGACGACCGTAG  
TGATGAATCTCTCCTGGCGGGAACAGCAAATATCACCCGGTCCGGCAAACAAATTCTCGTCCCTGA  
TTTTTACCACCCCTGACCGCGAATGGTGAGATTGAGAATATAACCTTTTATTCCCAGCGGTGCG  
TCGATAAAAAATCGAGATAACCGTTGGCCTCAATCGGCGTTAAACCCGCCACCAGATGGGCATTA  
AACGAGTATCCCGGCAGCAGGGGATCATTTTGCCTTCAGCCATACTTTTCATACTCCCGCCATTC  
AGAG

I. Plasmid pJT166: The sequence of sfGFP<sup>Opt</sup>[1UAU-135UAG-151UAA] is shown in **green** text, tRNA<sup>Ty2</sup><sub>AUA</sub> is shown in **indigo** text, and MatRNA(6)<sup>Pyl</sup><sub>CUA</sub> is shown in **peach** text. Promoter sequences are **bold**.

Created with SnapGene®




AAGAAACCAATTGTCCATATTGCATCAGACATTGCCGTCACCTGCGTCTTTTACTGGCTCTTCTCGCT  
AACCAAACCGGTAACCCCGCTTATTAAGCATTCTGTAACAAAGCGGGACCAAAGCCATGACAAA  
AACGCGTAACAAAAGTGTCTATAATCACGGCAGAAAAGTCCACATTGATTATTTGCACGGCGTCAC  
ACTTTGCTATGCCATAGCATTATTTTATCCATAAGATTAGCGGATCCTAC**CTGACGCTTTTTATCGCAA**  
**CTCTCTACTG**TTTCTCCATACCCGTTTTTTGGGCTAACAGGAGGAAGCTAAAT**TATAGCAAGGGCGA**  
**AGAGTTATTCACAGGGGTTGTCCCTATTCTTGTAGAATTGGATGGAGACGTAACGGCCATAAAT**  
**TCTCCGTACGCGGGGAAGGCGAAGGTGATGCTACAAATGGGAAATTAACCTGAAATTTATTTG**  
**CACAACCGGAAAATTACCTGTGCCTTGGCCTACTCTGGTCACGACCTAACATACGGTGTACAG**  
**TGCTTTTACGTTACCCAGATCATATGAAGCGCCACGATTTCTTCAAGAGTGCAATGCCTGAGGG**  
**GTACGTTCAAGAACGTACCATTTCTGTTAAGGACGATGGAACCTACAAAACCCGTGCAGAGGTC**  
**AAGTTTGAAGGTGACACTTTAGTTAACCGTATTGAATTAAGGGCATTGATTTCAAAGAAGACGG**  
**ATAGATTTTAGGTCATAAGCTGGAGTACAATTTAACTCTCACACGTATAAATTACAGCTGACA**  
**AACAGAAGAACGGTATTAAGCGAATTTCAAGATCCGTCATAACGTAGAAGATGGAAGCGTACA**  
**ATTGGCGGATCACTACCAACAGAATACTCCTATCGGCGACGGCCCTGTGCTGCTTCCCGACAAC**  
**CATTACTTGTCCAACGAGAGCGTATTATCAAAGGACCCAAACGAGAAACGCGACCATATGGTGC**  
**TTTTAGAGTTCTGTGACCGCCGCTGGCATCACCCATGGTATGGACGAGCTGTACAAGGGCTCACA**  
**TCATCATCATCATTG**ACTCGAGATCTGCAGCTGGTACCATATGGGAATTCGAAGCTTGGCTGT  
TTTGGCGGATGAGAGAAGATTTTCAGCCTGATACAGATTAATCAGAACGCAGAAGCGGTCTGATA  
AAACAGAATTTGCCGCGCAGTAGCGCGGTGGTCCCACCTGACCCCATGCCGAACCTCAGAAGT  
GAAACGCCGTAGCGCCGATGGTAGTGTGGGGTCTCCCATGCGAGAGTAGGGAACCTGCCAGGCA

TCAAATAAAACGAAAGGCTCAGTCGAAAGACTGGGCCTTTCGTTTTATCTGTTGTTTGTCCGGTGAA  
CGCTCTCCTGAGTAGGACAAATCCGCCGGGAGCGGATTTGAACGTTGCGAAGCAACGGCCCGGA  
GGGTGGCGGGCAGGACGCCCGCCATAAACTGCCAGGCATCAAATTAAGCAGAAGGCCATCCTGA  
CGGATGGCCTTTTTGCGTTTCTACAAACTCTTTTGTATTTTTCTAAATACATTCAAATATGTATCC  
GCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAA  
CATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTCCTTCTGTTTTGCTCACCCAGAAA  
CGCTGGTCAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTACATCGAACTGGAT  
CTAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTT  
AAAGTTCTGCTATGTGGCGCGGTATTATCCCGTGTGACGCCGGGCAAGAGCAACTCGGTCCGCC  
CATACTATTCTCAGAATGACTTGGTTGAGTACTACCAGTCACAGAAAAGCATCTTACGGATGG  
CATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACTGCGGCCAACTTACT  
TCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAA  
CTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCAG  
ATGCCTGTAGCAATGGCAACAACGTTGCGCAAACCTAATACTGGCGAACTACTTACTCTAGCTTCC  
CGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCT  
TCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTG  
CAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGC  
AACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACT  
GTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACCTTCATTTTAATTTAAAAGGATCTA  
GGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTAACGTGAGTTTTCGTTCCACTGAGCG  
TCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTCTGCGCGTAATCTGCTGCT  
TGCAAAACAAAAAACCACCGCTACCAGCGGTGGTTTGTGGCGGATCAAGAGCTACCAACTCTTT  
TTCCGAAGGTAACCTGGCTTACGACAGAGCGCAGATACCAAATACTGTCTTCTAGTGTAGCCGTAGT  
TAGGCCACCCTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAG  
TGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGAT  
AAGGCGCAGCGGTCCGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACC  
TACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAA  
GGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGG  
GGGAAACGCCTGGTATCTTTATAGTCCTGTCCGGTTTTCGCCACCTCTGACTTGAGCGTCGATTTTT  
GTGATGCTCGTCAGGGGGGGCGGAGCCTATGGAAAACGCCAGCAACGCGGCCTTTTTACGGTTC  
CTGGCCTTTTGTGGCCTTTTGTCCACATGTTCTTTCTGCGTTATCCCCTGATTCTGTGGATAACC  
GTATTACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTC  
AGTGAGCGAGGAAGCGGAAGAGCGCCTGATGCGGTATTTTCTCCTTACGCATCTGTGCGGTATTT  
CACACCGCATATGGTGCCTCTCAGTACAATCTGCTCTGATGCCGCATAGTTAAGCCAGTATACAC  
TCCGCTATCGCTACGTGACTGGGTGCTGCTGCGCCCCGACACCCGCCAACACCCGCTGACGCG  
CCCTGACGGGCTTGTCTGCTCCGCATGCAAAAAAGCCTGCTCGTTGAGCAGGCTTTTCGAATTTG  
**GCGAGAGACCGGGGTGTCGAACCCGCTATGTAGTTTTAGAGACCCGCTGGTCCCGGACC**  
**GTCCCCAATGCGGGGCGCATCTTACTGCGCAGATACGCCCTCGTCAATCCCTAATAGCAAAA**  
**TGCCTCGGCATCCGCTTACAGACAAGCTGTGACCGTCTCCGGGAGCTGCATGTGTCAGAGGTTTT**  
CACCGTCATACCGAAACGCGCGAGGCAGCAGATCAATTCGCGCGCGAAGGCCGAAGCGGAAGCT  
TAAAAAAAATCCTTAGCTTTCGCTAAGGATCTGCAGGTGACTCTAGAGGATCCT**TGGTCCGGGG**  
**GCCGGATTTGAACCGACGATCTTCGGGTTTATAGCCCGACGAGCTACCAGGCTGCTCCACCCCG**  
**CGGAATTCAGCGTTACAAGTATTACACAAAGTTTTTATGTTGAGAATATTTTTTTGATGGGGCGC**  
**CACTTATTTTTGATCGTTGCTCAAAGAAGCGGCGCCAGCATAATGTGCCTGTCAAATGGACGAA**  
GCAGGGATTCTGCAAACCCTATGCTACTCCGTCAAGCCGTCAATTGTCTGATTCTGTTACCAATTAT  
GACAACTTGACGGCTACATCATTCACTTTTTCTTACAACCGGCACGGAACCTCGCTCGGGCTGGC  
CCCGGTGCATTTTTAAATACCCGCGAGAAATAGAGTTGATCGTCAAACCAACATTGCGACCGAC  
GGTGGCGATAGGCATCCGGGTGGTGCTCAAAGCAGCTTCGCCTGGCTGATACGTTGGTCCTCG  
CGCCAGCTTAAGACGCTAATCCCTAACTGCTGGCGGAAAAGATGTGACAGACGCGACGGCGACAA  
GCAAACATGCTGTGCGACGCTGGCGATATCAAATTGCTGTCTGCCAGGTGATCGCTGATGTACT  
GACAAGCCTCGCGTACCCGATTATCCATCGGTGGATGGAGCGACTCGTTAATCGCTTCCATGCGC  
CGCAGTAACAATTGCTCAAGCAGATTTATCGCCAGCAGCTCCGAATAGCGCCCTTCCCCTTGCCC  
GGCGTTAATGATTTGCCCAAACAGGTGCTGAAATGCGGCTGGTGCCTTCATCCGGGCGAAAGA  
ACCCCGTATTGGCAAATATTGACGGCCAGTTAAGCCATTGATGCCAGTAGGCGCGCGGACGAAAG

TAAACCCACTGGTGATACCATTCGCGAGCCTCCGGATGACGACCGTAGTGATGAATCTCTCCTGG  
 CGGGAACAGCAAAATATCACCCGGTCCGGCAAACAATTCTCGTCCCTGATTTTTACCACCCCCTG  
 ACCGCGAATGGTGAGATTGAGAATATAACCTTTTCATTCCCAGCGGTCCGGTTCGATAAAAAAATCGAG  
 ATAACCGTTGGCCTCAATCGGCGTTAAACCCGCCACCAGATGGGCATTAACGAGTATCCCGGCA  
 GCAGGGGATCATTTTGCCTTCAGCCATACTTTTCATACTCCCGCCATTTCAGAG

m. Plasmid pJT159: The sequence of AzFRS.2.t1 is shown in **green** text, MaPyIRS(166S) is shown in **magenta** text, and MatRNA(6)<sup>Pyl</sup><sub>CUA</sub> is shown in **indigo** text. Promoter sequences are **bold**.

Created with SnapGene®




GACAGTAAGACGGGTAAGCCTGTTGATGATACCGCTGCCTTACTGGGTGCATTAGCCAGTCTGAA  
 TGACCTGTCACGGGATAATCCGAAGTGGTCAGACTGGAAAATCAGAGGGCAGGAAGTCTGAACA  
 GCAAAAAGTCAGATAGCACCACATAGCAGACCCGCCATAAAACGCCCTGAGAAGCCCCTGACGG  
 GCTTTTCTTGATTATGGGTAGTTTCCTTGCATGAATCCATAAAAGGCGCCTGTAGTGCCATTTACC  
 CCCATTCACTGCCAGAGCCGTGAGCGCAGCGAAGTGAATGTCACGAAAAGACAGCGACTCAGGT  
 GCCTGATGGTCGGAGACAAAAGGAATATTCAGCGATTTGCCCGAGCTTGCGAGGGTGCTACTTAA  
 GCCTTTAGGGTTTTAAGGTCTGTTTTGTAGAGGAGCAAACAGCGTTTTCGACATCCTTTTGTAAATAC  
 TCGGGAAGTACTAAAGTAGTGAGTTATACACAGGGCTGGGATCTATTCTTTTTATCTTTTTTATT  
 CTTTCTTTATTCTATAAATTATAACCACTTGAATATAAACAAAAAACACACAAAGGTCTAGCGGAA  
 TTTACAGAGGGTCTAGCAGAATTTACAAGTTTTCCAGCAAAGTCTAGCAGAATTTACAGATACCCA  
 CAACTCAAAGGAAAAGGACTAGTAATTATCATTGACTAGCCCATCTCAATTGGTATAGTGATTA  
 TCACTAGACCAATTGAGATGTATGTCTGAATTAGTTGTTTTCAAAGCAAATGAACTAGCGATTAGT  
 CGCTATGACTTAACGGAGCATGAAACCAAGCTAATTTTATGCTGTGTGGCACTACTCAACCCACG



ATTGAAAACCCTACAAGGAAAGAACGGACGGTATCGTTCACTTATAACCAATACGCTCAGATGATG  
AACATCAGTAGGGAAAATGCTTATGGTGTATTAGCTAAAGCAACCAGAGAGCTGATGACGAGA  
GTGGAAATCAGGAATCCTTTGGTTAAAGGCTTTGAGATTTTCCAGTGGACAACTATGCCAAGTTC  
TCAAGCGAAAAATTAGAATTAGTTTTAGTGAAGAGATATTGCCTTATCTTTTCCAGTTAAAAA  
CATAAATATAATCTGGAACATGTTAAGTCTTTTGAACAAATACTCTATGAGGATTTATGAGTGGT  
TATTAAGAAGAACTAACACAAAAGAAAACCTCACAAGGCAAATATAGAGATTAGCCTTGATGA  
ATTAA GTTCATGTTAATGCTTGAAAATAACTACCATGAGTTTAAAAGGCTTAACCAATGGGTTTTGAAACCA  
ATAAGTAAAGATTTAAACACTTACAGCAATATGAAATTGGTGGTTGATAAGCGAGGCCGCCGACT  
GATACGTTGATTTTCCAAGTTGAACTAGATAGACAAATGGATCTCGTAACCGAACTTGAGAACA  
CAGATAAAAATGAATGGTGACAAAATACCAACAACCATTACATCAGATTCCTACCTACATAACGGAC  
TAAGAAAAACACTACACGATGCTTTAACTGCAAAAATTCAGCTCACCAGTTTTGAGGCAAAATTTT  
GAGTGACATGCAAAGTAAGCATGATCTCAATGGTTCGTTCTCATGGCTCACGCAAAAACAACGAAC  
CACACTAGAGAACATACTGGCTAAATACGGAAGGATCTGAGGTTCTTATGGCTCTTGATCTATCA  
GTGAAGCATCAAGACTAACAAACAAAAGTAGAACAACCTGTTACCGTTACATATCAAAGGGAAAAC  
TGCCATAAAAACAAAAGAGTTTGTAGAAACGCAAAAAGGCCATCCGTCAGGATGGCCTTCTGCTT  
AATTTGATGCCTGGCAGTTTATGGCGGGCGTCCTGCCCGCCACCCTCCGGGCCGTTGCTTCGCA  
CGTTCAAATCCGCTCCCGGCGGATTTGTCTACTCAGGAGAGCGTTCACCGACAAACAACAGATA  
AAACGAAAGGCCAGTCTTTGACTGAGCCTTTGTTTTATTTGATGCCTGGCAGTTCCCTACTCT  
CGCATGGGGAGACCCACACTACCATCGGCGCTACGGCCTTTCACTTCTGAGTTCGGCATGGGGT  
CAGGTGGGACCACCGCGCTACTGCCGCCAGGCAAATTCGTTTTATCAGACCGCTTCTGCGTTCT  
GATTTAATCTGTATCAGGCTGAAAATCTTCTCATCCGCAAAACAGCCTTAGTGGTGGTGGTGG  
TGGTGCCTCGAGAGCGGCCGCTATAATCTCTTTCTAATTGGCTCTAAAATCTTTATAAGTTCTTCA  
GCTACAGCATTTTTTTAAGCGCATTGGATGCAATTCCTTATTTTTAAATAAACTCTCTAACTCCTCA  
TAGCTATTAATCTGCAAATCTCCACCAAATTTTTCTGGCCCTTTTATGGTTAAAGGATATTCAAGG  
AAGTATTTAGCTATCTCCATTATTGGATTTCTTCAACAACCTCCAGCTGGGCAGTATGCTTTCTTT  
ATCTTAGCCCTAATCTCTTCTGGAGAGTCATCAACAGCTATAAAATTCCCTTTTGAAGAACTCATC  
TTTCTTCTCCATCCAACCCGTTAAGACAGGGTTGTGAATACAAACAACCTTTTTTGGTAAAAG  
CTCCCTTGCTAACATGTGTATTTTTCTCTGCTCCATCCCTCCAACAGCAACATCAACGCCCTATA  
ATGACAACCATTAACCTGCATTATTGGATAGATAACTTCAGCAACCTTTGGATTTTCATCCTCTCT  
TGCTATAAGTTCCATACTCCTTCTTGCCCTTTTTAAGGTAGTTTTTAAAGCCAATCTATAGACATTC  
AGTGATAATCCTTATCAAGCATATAAGTACTTCCATAAACATATTTTGCCTTAAACCCATTGCT  
TCAAAAACCTTTTTTGTATAATCTCCTATTTTTCTAATCTCATCCAACCTCTCCTTCTGGTTTAAATA  
GGCGTGTAATCAGCCAACAATATAATTATCAAATCCAGCATTGTGTAATCAATCATCTTTTT  
TATTTGGAGATAATGCCCTAAATGTATTTTACCCTTGGTTCAAACCTATCAGAGCAGATTTTTT  
ATCCTTTTTTAAACCTCTCTTAACTCTTCTCCTCGCTGATAATTTAGATGTGTTTCTCTTTATCATT  
CAAATTCGTCCATATGTGTTTCTGTGTGAAATTGTTATCCGCTCACAATTCACACAACATACGA  
GCCGGAAGCATAAAGTGTAAGCCTGGGGTGCCTAATGAGTGAGCTAACTCACATTAATTGCGT  
TGCGCTCACTGCCCGCTTCCAGTCGGGAAACCTGTGCGTCCAGCTGCATTAATGAATCGGCCAA  
CGCGCGGGGAGAGGCGGTTTGCATATTGGGCGCTTCTCATAGCTCACGCTGTAGGTATCTCAGT  
TCGGCTCAGTCGAAAGACTGGGCCTTGTGTTGTGAGCTCCCGGTCATCAATCATCCCCATAATCCTT  
GTTAGATTATCAATTTAAAAAATAACAGTTGTCAGCCTGTCCCGCTTAAATATCATACGCCGTTA  
TACGTTGTTACGCTTTGAGGAATCCCATATGACAGTCAAATACACCGATGCACAGATTCAGCGT  
CTGCGTGAATATGGTAATGGCACCTATGAACAGAAAGTGTTTGAAGATCTGGCAAGCCGTGATG  
CAGCATTTAGCAAAGAAATGAGCGTTGCAAGCACCGACAATGAGAAAAAATCAAAGGCATGA  
TTGCAAACCCGAGCCGTCATGGTCTGACCCAGCTGATGAATGATATTGCAGATGCACTGGTTGC  
CGAAGGTTTTATTGAAGTTCGTACCCGATTTTTCATCAGCAAAGATGCCCTGGCACGTATGACCA  
TTACCGAAGATAAACCGCTGTTCAAACAGGTGTTTTGGATTGATGAAAAACGTGCACTGCGTCC  
GATGCTGGCACCGAATCTGTATAGCGTTATGCGTGATCTGCGCGATCATAACCGATGGTCCGGT  
AAAATCTTTGAAATGGGTAGCTGCTTTCGCAAAGAAAGCCATAGCGGTATGCATCTGGAAGAAT  
TTACCATGCTGTCACTGGTAGATATGGGTCCGCGTGGTGTGCAACCGAAGTTCTGAAAACTA  
TATTAGCGTTGTGATGAAAGCAGCAGGTCTGCCGATTATGATCTGGTTCAAGAAGAAAGCGAC  
GTCTACAAAGAAACCATTGATGTGGAATTAACGGCCAAGAAGTTTGTAGCGCAGCAGTTGGTC  
CGCATTATCTGGATGCAGCACATGATGTGCATGAACCGTGGTCAGGTGCAGTTTTTGGTCTGGA  
ACGTCTGCTGACCATTCTGAGAAATATAGCACCGTTAAAAAAGGTGGTGGCAGCATTAGCTAT

**CTGAATGGTGCCAAGATCAATTG**ACTGCAGTTTCAAACGCTAAATTGCCTGATGCGCTACGCTTAT  
CAGGCCTACATGATCTCTGCAATATATTGAGTTTGCGTGCTTTTGTAGGCCGGATAAAGGCGTTCAC  
GCCGCATCCGGCAAGAAACAGCAAACAATCCAAAACGCCGCGTTCAGCGGCGTTTTTTCTGCTTTT  
CTTCGCGAATTAATTCCGCTTCGCAACATGTGAGCACCGGTTTATTGACTACCGGAAGCAGTGTGA  
CCGTGTGCTTCTCAAATGCCTGAGGCCAGTTTGTCTCAGGCTCTCCCCGTGGAGGTAATAATTGAC  
GATATGATCAGTGCACGGCTAACTAAGCGGCCTGCTGACTTTTCTCGCCGATCAA**AAGGCATTTTG**  
**CTATTAAGGGATTGACGAGGGCGTATCTGCGCAGTAAGATGCGCCCCGCATTGGGGGACGGTC**  
**CGGCGACCAGCGGGTCTCTAAAACCTAGCATAGCGGGGTTGACACCCCCGGTCTCTCGCCA**AAT  
TCGAAAAGCCTGCTCAACGAGCAGGCTTTTTTGCATGCTCGAGCAGCTCAGGGTCAATTTGCTTT  
CGAATTTCTGCCATTCATCCGCTTATTATCACTTATTCAGGCGTAGCACCAGGCGTTTAAGGGCAC  
CAATAACTGCCTTAAAAAAATTACGCCCGCCCTGCCACTCATCGCAGTACTGTTGTAATTCATTAA  
GCATTCTGCCGACATGGAAGCCATCACAGACGGCATGATGAACCTGAATCGCCAGCGGCATCAGC  
ACCTTGTGCGCTTGCGTATAATATTTGCCCATGGTGAAAACGGGGGCGAAGAAGTTGTCCATATTG  
GCCACGTTTTAAATCAA**AACTGGTGAAACTCACCCAGGGATTGGCTGAGACGAAAAACATATTCTCA**  
ATAAACCCTTTTAGGGAAATAGGCCAGGTTTTTACCAGTAACACGCCACATCTTGCGAATATATGTGT  
AGAAACTGCCGGAATCGTCGTGGTATTCACTCCAGAGCGATGAAAACGTTTCAGTTTGTCTCATGG  
AAAACGGTGTAACAAGGGTGAACACTATCCCATATCACCCAGCTCACCGTCTTTCATTGCCATACGG  
AATCCGGATGAGCATTATCAGGCGGGCAAGAATGTGAATAAAGGCCGGATAAAACTTGTGCTTA  
TTTTTCTTTACGGTCTTTAAAAGGCCGTAATATCCAGCTGAACGGTCTGGTTATAGGTACATTGAG  
CAACTGACTGAAATGCCTCAA**AAATGTTCTTTACGATGCCATTGGGATATATCAACGGTGGTATATCC**  
AGTGATTTTTTTCTCCATTTTAGCTTCCTTAGCTCCTGAAAATCTCGATAACTCAAAAATACGCCCG  
GTAGTGATCTTATTTCAATTATGGTGAAAGTTGGAACCTCTTACGTGCCGATCAACGTCTCATTTCG  
CCTCATCCTGTCTCTTGATCACTACCGCATTAAAGCATATCGATGATAAGCTGTCAAACATGAGCGT  
TCTTCGGGGCGAAA**ACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGT**  
GCACCCA**ACTGATCTTCAGCATCTTTTACTTTACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGG**  
CAA**ATGCCGCAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCATACTCTTCCTTTTT**  
CAATATTATTGAAGCATT**TATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAA**  
AAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCACCTGACGTCTAAGAAACCAT  
TATTATCATGACATTAACCTATAAAAATAGGCGTATCACGAGGCCCTTTCGTCTTCAAGAATT

n. Plasmid pJT48: The sequence of pCNFRS is shown in **magenta** text. The promoter sequence is **bold**.




```

GACAGTAAGACGGGTAAGCCTGTTGATGATACCGCTGCCTTACTGGGTGCATTAGCCAGTCTGAA
TGACCTGTCACGGGATAATCCGAAGTGGTCAGACTGGAAAATCAGAGGGCAGGAAGTCTGAACA
GCAAAAAGTCAGATAGCACCATAGCAGACCCGCCATAAAACGCCCTGAGAAGCCCGTGACGG
GCTTTTCTTGATTATGGGTAGTTTCCTTGCATGAATCCATAAAAGGCGCCTGTAGTGCCATTTACC
CCATTCACTGCCAGAGCCGTGAGCGCAGCGAAGTGAATGTCACGAAAAGACAGCGACTCAGGT
GCCTGATGGTCGGAGACAAAAGGAATATTCAGCGATTTGCCCGAGCTTGCAGGGGTGCTACTTAA
GCCTTTAGGGTTTTAAGGTCTGTTTTGTAGAGGAGCAAACAGCGTTTGCAGACATCCTTTTGAATAC
TGCGGAAGTACTAAAGTAGTGAGTTATACACAGGGCTGGGATCTATTCTTTTTATCTTTTTTTATT
CTTTCTTTATTCTATAAATTATAACCACTTGAATATAAACAAAAAACACACAAAGGTCTAGCGGAA
TTTACAGAGGGTCTAGCAGAATTTACAAGTTTTCCAGCAAAGGTCTAGCAGAATTTACAGATACCCA
CAACTCAAAGGAAAAGGACTAGTAATTATCATTGACTAGCCCATCTCAATTGGTATAGTGATTAATA
TCACCTAGACCAATTGAGATGTATGTCTGAATTAGTTGTTTTCAAAGCAAATGAACTAGCGATTAGT
CGCTATGACTTAACGGAGCATGAAACCAAGCTAATTTTATGCTGTGTGGCACTACTCAACCCCACG
ATTGAAAACCCTACAAGGAAAGAACGGACGGTATCGTTCACCTTATAACCAATACGCTCAGATGATG
AACATCAGTAGGGAAAATGCTTATGGTGTATTAGCTAAAGCAACCAGAGAGCTGATGACGAGAAGT
GTGGAAATCAGGAATCCTTTGGTTAAAGGCTTTGAGATTTTCCAGTGGACAAACTATGCCAAGTTC
TCAAGCGAAAATTAGAATTAGTTTTTAGTGAAGAGATATTGCCTTATCTTTTCCAGTTAAAAAATT
CATAAAATATAATCTGGAACATGTTAAGTCTTTTGAACAAATACTCTATGAGGATTTATGAGTGGT
TATTAAGAAGAACTAACACAAAAGAAAAGTCAACAAGGCAAATATAGAGATTAGCCTTGATGAATTTAA
GTTTCATGTTAATGCTTGAATAAAGTAACTACCATGAGTTTAAAGGCTTAAACCAATGGGTTTTGAAACCA
ATAAGTAAAGATTTAAACACTTACAGCAATATGAAATTGGTGGTTGATAAGCGAGGCCGCCCGACT
    
```

GATACGTTGATTTTCCAAGTTGAACTAGATAGACAAATGGATCTCGTAACCGAACTTGAGAACAAC  
CAGATAAAAATGAATGGTGACAAAATACCAACAACCATTACATCAGATTCCTACCTACATAACGGAC  
TAAGAAAAACACTACACGATGCTTTAACTGCAAAAATTCAGCTCACCAGTTTTGAGGCAAAAATTTT  
GAGTGACATGCAAAGTAAGCATGATCTCAATGGTTTCGTTCTCATGGCTCACGCAAAAACAACGAAC  
CACACTAGAGAACATACTGGCTAAATACGGAAGGATCTGAGGTTCTTATGGCTCTTGTATCTATCA  
GTGAAGCATCAAGACTAACAAACAAAAGTAGAACAACCTGTTACCGTTACATATCAAAGGGAAAAC  
TGTCATAAAAACAAAAGAGTTTGTAGAAACGCAAAAAGGCCATCCGTCAGGATGGCCTTCTGCTT  
AATTTGATGCCTGGCAGTTTATGGCGGGCGTCTGCCCGCCACCCTCCGGGCCGTTGCTTCGCAA  
CGTTCAAATCCGCTCCCGGCGGATTTGTCTACTCAGGAGAGCGTTCACCGACAAACAACAGATA  
AAACGAAAGGCCAGTCTTTCGACTGAGCCTTTCGTTTTATTTGATGCCTGGCAGTTCCTACTCT  
CGCATGGGAGACCCACACTACCATCGGCGCTACGGCCTTTCACTTCTGAGTTCGGCATGGGGT  
CAGGTGGGACCACCGCGCTACTGCCGCCAGGCAAATTCTGTTTTATCAGACCGCTTCTGCGTTCT  
GATTTAATCTGTATCAGGCTGAAAATCTTCTCTCATCCGCCAAAACAGCCTTAGTGGTGGTGGTGG  
TGGTGCTCGAGAGCGGCCGCTTATAATCTCTTTCTAATTGGCTCTAAAATCTTTATAAGTTCTTCA  
GCTACAGCATTTTTTAAATCCATTGGATGCAATTCCTATTTTTAAATAAACTCTCTAACTCCTCAT  
AGCTATTAAGTGTCAAATCTCCACCAAATTTTTCTGGCCTTTTTATGGTTAAAGGATATTCAAGGA  
AGTATTTAGCTATCTCCATTATTGGATTTCTTCAACAACCTCCAGCTGGGCAGTATGCTTTCTTTA  
TCTTAGCCCTAATCTCTTCTGGAGAGTCATCAACAGCTATAAAATTCCTTTTTGAAGAACTCATCT  
TTCCTTCTCCATCAAACCGTTAAGACAGGGTGTGAATACAAACAACCTTTTTTGGTAAAAGC  
TCCCTTGCTAACATGTGATTTTTCTCTGCTCCATCCCCCAACTGCAACATCAACGCCAAGATA  
ATGAGCACCATTAACCTGCATTATTGGATAGATAACTTCAGCAACCTTTGGATTTTCATCCTCTCT  
TGCTATAAGTTCCATACTCCTTCTTGCTCTTTTTAAGGTAGTTTTAAAGCCAATCTATAGACATTC  
AGTGATAATCCTTATCAAGCATCCATTCCTTCCATAAACATATTTTGCCTTTAACCCATTGCT  
TCAAAAACCTTTTTGTTATAATCTCCTATTTTTCTAATCTCATCCAACCTCTCCTTTCTGGTTAAATA  
GGCATGTAAATCAGCCAAAACATAATTATCAAATCCAGCATTGTTAAATCAATCATCTTTTT  
TATTTGGAGATAATGCCCTAAATGATTTTTACCACCTGGTTCAAACCTATCAGAGCAGATTTTTTC  
ATCTTTTTTTAAAACCTCTCTTAACTCTTCTCGCTGATAATTTAGATGTGTTTCTTTTATCATT  
CAAATTCGTCCATATGTGTTTCTGTGTGAATTGTTATCCGCTCACAAATTCACACAACATACGA  
GCCGGAAGCATAAAGTGTAAAGCCTGGGGTGCCTAATGAGTGAGCTAACTCACATTAATTGCGT  
TGCGCTCACTGCCCGCTTTCAGTCGGGAAACCTGTCTGTGCCAGCTGCATTAATGAATCGGCCAA  
CGCGCGGGGAGAGGGCGGTTTGCATATTGGGCGCTTTCATAGCTCACGCTGTAGGTATCTCAGT  
TCGGTGTAGGTGTTTCGCTCCAAGCTGGGCTGTGTGCCGAACCCAGAGTCCCGCTTATTTGCCG  
ACTACCTTGGTGATCTCGCTTTCACGTAGTGGACAAATTCCTCAACTGATCTGCGCGCGAGGCC  
AAGCGATCTTCTTCTGTCCAAGATAAGCCTGTCTAGCTTCAAGTATGACGGGCTGATACTGGGCC  
GGCAGGCGCTCCATTGCCAGTCGGCAGCGACATCCTTCGGCGCGATTTTGGCGTTACTGCGC  
TGTACCAAATGCGGGACAACGTAAGCACTACATTTTCGCTCATCGCCAGCCAGTCGGGCGGGCGAG  
TTCCATAGCGTTAAGTTTTATTAGCGCCTCAAATAGATCCTGTTCCAGGAACCGGATCAAAGAGT  
TCCTCCGCCGCTGGACCTACCAAGGCAACGCTATGTTCTCTTGTCTTTTGTGAGCAAGATAGCCAGA  
TCAATGTGATCGTGGCTGGCTCGAAGATACCTGCAAGAATGTCATTGCGCTGCCATTCTCCAAAT  
TGCAGTTCGCGCTTAGCTGGATAACGCCACGGAATGATGTCGTGTCGCAACAATGGTGACTTC  
TACAGCGCGGAGAATCTCGCTCTCTCCAGGGGAAGCCGAAGTTTCCAAAAGGTGCTTGATCAAAG  
CTCGCCGCGTTGTTTCATCAAGCCTTACGGTCACCGTAACCAGCAAATCAATATCACTGTGTGGCT  
TCAGGCCGCCATCCACTGCGGAGCCGTACAAATGTACGGCCAGCAACGTCCGTTTCGAGATGGCG  
CTCGATGACGCCAACTACCTCTGATAGTTGAGTCGATACTTCGGCGATCACCGCTTCCCTCATGCG  
AAACGATCCTCATCCTGTCTCTTGTACTACTACCGCATTAAAGCATATCGATGATAAGCTGTCAAACA  
TGAGCGTTCTTCGGGGCGAAAACCTCTCAAGGATCTTACCCTGTTGAGATCCAGTTCGATGTAACC  
CACTCGTGCACCCAACTGATCTTTCAGCATCTTTTACTTTTACCAGCGTTTCTGGGTGAGCAAAAAC  
AGGAAGGCAAAATGCCGCAAAAAGGGAATAAGGGCGACACGAAATGTTGAATACTCATACTCT  
TCCTTTTTCAATATTATTGAAGCATTTATCAGGGTATTGTCTCATGAGCGGATACATATTTGAATGT  
ATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCACCTGACGTCTAA  
GAAACCATTATTATCATGACATTAACCTATAAAAATAGGCGTATCACGAGGCCCTTTCGTCTTCAAG  
AATT

o. Plasmid pJT156: The sequence of *MmPylRS* is shown in **magenta** text while *MmtRNA<sup>Pyl</sup><sub>UUA</sub>* is shown in **indigo** text. Promoter sequences are **bold**.



```

TCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAACAAATAGCTAGC
TCACTCGGTCGCTACGCTCCGGGCGTGAGACTGCGGCGGGCGCTGCGGACACATACAAAGTTAC
CCACAGATTCCGTGGATAAGCAGGGGACTAACATGTGAGGCAAAACAGCAGGGCCGCGCCGGTG
GCGTTTTTCCATAGGCTCCGCCCTCCTGCCAGAGTTCACATAAACAGACGCTTTTTCCGGTGATCT
GTGGGAGCCGTGAGGCTCAACCATGAATCTGACAGTACGGGCGAAACCCGACAGGACTTAAAGAT
CCCCACCGTTTTCCGGCGGGTTCGCTCCCTCTTGCGCTCTCCTGTTCCGACCCTGCCGTTTACCGGA
TACCTGTTCCGCCTTTCTCCCTTACGGGAAGTGTGGCGCTTTCTCATAGCTCACACACTGGTATCT
CGGCTCGGTGTAGGTCGTTTCGCTCCAAGCTGGGCTGTAAGCAAGAACTCCCCGTTTACGCCGACT
GCTGCGCCTTATCCGGTAACTGTTCACTTGAGTCCAACCCGAAAAGCACGGTAAAACGCCACTG
GCAGCAGCCATTGGTAACTGGGAGTTCGCAGAGGATTTGTTAGCTAAACACGCGGTTGCTCTTG
AAGTGTGCGCCAAAGTCCGGCTACACTGGAAGGACAGATTTGGTTGCTGTGCTCTGCGAAAGCCA
GTTACCACGGTTAAGCAGTTCCCAACTGACTTAACTTCGATCAAACCACCTCCCAGGTGGTTT
TTTCGTTTACAGGGCAAAAGATTACGCGCAGAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTC
TACTGAACCGCTCTAGATTTCAAGTCAATTTATCTCTTCAAATGTAGCACCTGAAGTCAGCCCCATA
CGATATAAGTTGTAATTCTCATGTTAGTCATGCCCGCGGCCACCGGAAGGAGCTGACTGGGTTG
AAGGCTCTCAAGGGCATCGGTGAGATCCCGGTGCCTAATGAGTGAGCTAACTTACATTAATTGC
GTTGCGCTCACTGCCCGCTTTCCAGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCC
AACGCGCGGGGAGAGGGCGTTTTCGATTGGGCGCCAGGGTGGTTTTTCTTTTACCAGTGAGA
    
```

CGGGCAACAGCTGATTGCCCTTACCGCCTGGCCCTGAGAGAGTTGCAGCAAGCGGTCCACGCT  
GGTTTGCCCCAGCAGGCGAAAATCCTGTTTGATGGTGGTTAACGGCGGGATATAACATGAGCTGT  
CTTCGGTATCGTCGTATCCCACTACCGAGATGTCCGCACCAACGCGCAGCCCGGACTCGGTAATG  
GCGCGCATTGCGCCCAGCGCCATCTGATCGTTGGCAACCAGCATCGCAGTGGGAACGATGCCCT  
CATTGAGCATTGTCATGGTTTGTGAAAACCGGACATGGCACTCCAGTCGCCTTCCCGTTCCGCTA  
TCGGCTGAATTTGATTGCGAGTGAGATATTTATGCCAGCCAGCCAGACGCAGACGCGCCGAGACA  
GAACTTAATGGGCCCCTAACAGCGCGATTTGCTGGTGACCCAATGCGACCAGATGCTCCACGCC  
CAGTCGCGTACCGTCTTCATGGGAGAAAATAATACTGTTGATGGGTGTCTGGTCAGAGACATCAAG  
AAATAACGCCGGAACATTAGTGCAGGCAGCTTCCACAGCAATGGCATCCTGGTCATCCAGCGGAT  
AGTTAATGATCAGCCCCTGACGCGTTGCGCGAGAAGATTGTGCACCGCCGCTTTACAGGCTTCG  
ACGCCGCTTCGTTCTACCATCGACACCACCAGCTGGCACCCAGTTGATCGGCGCGAGATTTAAT  
CGCCGCGACAATTTGCGACGGCGCGTGCAGGGCCAGACTGGAGGTGGCAACGCCAATCAGCAAC  
GACTGTTTGCCCGCCAGTTGTTGTGCCACGCGGTTGGGAATGTAATTCAGCTCCGCCATCGCCG  
TTCCACTTTTTCCCGCGTTTTTCGCAGAAACGTGGCTGGCCTGGTTCACCACGCGGGAAACGGTCT  
GATAAGAGACACCGGCATACTCTGCGACATCGTATAACGTTACTGGTTTACATTCACCACCCTGA  
ATTGACTCTCTTCCGGGCGCTATCATGCCATACCGCGAAAGGTTTTGCGCCATTCGATGGTGTCC  
GGGATCTCGACGCTCTCCCTTATGCGACTCCTGCATTAGGGAGCTGTTGACAATTAATCATCGGC  
**TCGTATAATGTGTGGAATTGTGAGCGGATAACAATTTACAAAGGAGGTGCGGCGCATGGATAA**  
**AAAACCACTAAACACTCTGATATCTGCAACCGGGCTCTGGATGTCCAGGACCGGAACAATTCAT**  
**AAAATAAAACACCACGAAGTCTCTGAAGCAAATCTATATTGAAATGGCATGCGGTGACCACC**  
**TTGTTGTAACAACCTCAGGAGCAGCAGGACTGCAAGAGCGCTCAGGCACCACAAATACAGGA**  
**AGACCTGCAAACGCTGCAGGGTTTTCGGATGAGGATCTCAATAAGTTCCTCACAAAGGCAAACGA**  
**AGACCAGACAAGCGTAAAAGTCAAGGTCGTTTCTGCCCTACCAGAACGAAAAGGCAATGCC**  
**AAAATCCGTTGCGAGAGCCCCGAAACCTCTTGAGAATACAGAAGCGGCACAGGCTCAACCTTCT**  
**GGATCTAAATTTTACCTGCGATACCGTTTTCCACCAAGAGTCAGTTTCTGTCCCGGCATCTGT**  
**TTCAACATCAATATCAAGCATTCTACAGGAGCAACTGCATCCGCACTGGTAAAAGGGAATACG**  
**AACCCATTACATCCATGTCTGCCCTGTTGAGGCAAGTCCCCCGCACTTACGAAGAGCCAGA**  
**CTGACAGGCTTGAAGTCTGTTAAACCCAAAAGATGAGATTTCCCTGAATTCCGGCAAGCCTTTC**  
**AGGGAGCTTGAGTCCGAATTGCTCTCTCGCAGAAAAAAGACCTGCAGCAGATCTACGCGGAA**  
**GAAAGGGAGAATTATCTGGGGAAACTCGAGCGTGAAATTACCAGGTTCTTTGTGGACAGGGGTT**  
**TTCTGGAAATAAAATCCCCGATCCTGATCCCTCTTGAGTATATCGAAAGGATGGGCATTGATAAT**  
**GATACCGAACTTTCAAACAGATCTTCAGGGTTGACAAGAACTTCTGCCTGAGACCCATGCTTG**  
**CTCCAAACCTTTACAACACTGCGCAAGCTTGACAGGGCCCTGCCTGATCCAATAAAAATTTTT**  
**GAAATAGGCCATGCTACAGAAAAGAGTCCGACGGCAAAGAACACCTCGAAGAGTTTACCATG**  
**CTGGCGTTTCGCGCAGATGGGATCGGGATGCACACGGGAAAATCTTGAAAGCATAATTACGGAC**  
**TTCTGAACCACCTGGGAATTGATTTCAAGATCGTAGGCGATTCTGCATGGTCTATGGGGATAC**  
**CCTTGATGTAATGCACGGAGACCTGGAATTTCTCTGCAGTAGTCGGACCCATACCGCTTGAC**  
**CGGGAATGGGGTATTGATAAACCTGGATAGGGGCAGGTTTCGGGCTCGAACGCCTTCTAAG**  
**GTTAAACACGACTTTAAAAATCAAGAGAGCTGCAAGGTCCGAGTCTTACTATAACGGGATTTT**  
**TACCAACTGTAA**GCGGCCGCGTTTTAAACGGTCTCCAGCTTGGCTGTTTTGGCGGATGAGAGAAG  
ATTTTCAGCCTGATACAGATTAATCAGAACGCAGAAGCGGTCTGATAAAACAGAATTTGCCTGGC  
GGCAGTAGCGCGGTGGTCCACCTGACCCCATGCCGAACCTCAGAAGTGAAACGCCGTAGCGCCG  
ATGGTAGTGTGGGGTCTCCCATGCGAGAGTAGGGAACCTGCCAGGCATCAAATAAAACGAAAGGC  
TCAGTCGAAAGACTGGGCCTTGTGTTGTGAGCTCCCGTTCATCAATCATCCCATAATCCTTGTTAG  
CCTGCAGGTAATTCGCTTCGCAACATGTGAGCACCGGTTTTATTGACTACCGGAAGCAGTGTGAC  
CGTGTGCTTCTCAAATGCCTGAGGCCAGTTTGTCTCAGGCTCTCCCGTGGAGGTAATAATTGACG  
ATATGATCAGTGCACGGCTAACTAAGCGGCCTGCTGACTTTCTCGCCGATCAA**AGGCATTTTGCT**  
**ATTAAGGGATTGACGAGGGCGTATCTGCGCAGTAAGATGCGCCCCGCATTGGAACCTGATCAT**  
**GTAGATCGAACGGACTTTAAATCCGTTGAGCCGGGTTAGATTCCCGGGGTTTCCGCCA**AATTCGA  
AAAGCCTGCTCAACGAGCAGGCTTTTTTGCATGCTCGAGCAGCTCAGGGTTCGAATTTGCCATGGC  
GGCCACCAGGTACCACCGGCGCCTCAGGCATTTGAGAAGCACACGGTCACACTGCTTCCGGTAG  
TCAATAAACCGGTAAACCAGCAATAGACATAAGCGGCTATTTAACGACCCTGCCCTGAACCGACGA  
CCGGGTCATCGTGGCCGGATCTTGCAGCCCTCGGCTTGAACGAATTGTTAGACATTATTTGCCG  
ACTACCTTGGTGTATCTCGCCTTTCACGTAGTGGACAAATTTCCAACCTGATCTGCGCGCGAGGCC

AAGCGATCTTCTTCTTGTCCAAGATAAGCCTGTCTAGCTTCAAGTATGACGGGCTGATACTGGGCC  
GGCAGGCGCTCCATTGCCAGTCGGCAGCGACATCCTTCGGCGCGATTTTGCCGTTACTGCGC  
TGTACCAAATGCGGGACAACGTAAGCACTACATTTTCGCTCATCGCCAGCCCAGTCGGGCGGCGAG  
TTCCATAGCGTTAAGGTTTCATTTAGCGCCTCAAATAGATCCTGTTTTCAGGAACCGGATCAAAGAGT  
TCCTCCGCGCTGGACCTACCAAGGCAACGCTATGTTCTCTTGCTTTTGTGTCAGCAAGATAGCCAGA  
TCAATGTCGATCGTGGCTGGCTCGAAGATACCTGCAAGAATGTCATTGCGCTGCCATTCTCAAAT  
TGCAGTTCGCGCTTAGCTGGATAACGCCACGGAATGATGTCGTCGTGCACAACAATGGTGACTTC  
TACAGCGCGGAGAATCTCGCTCTCTCCAGGGGAAGCCGAAGTTTCCAAAAGGTCGTTGATCAAAG  
CTCGCCGCGTTGTTTCATCAAGCCTTACGGTCACCGTAACCAGCAAATCAATATCACTGTGTGGCT  
TCAGGCCGCCATCCACTGCGGAGCCGTACAAATGTACGGCCAGCAACGTCGGTTCGAGATGGCG  
CTCGATGACGCCAACTACCTCTGATAGTTGAGTCGATACTTCGGCGATCACCGCTTCCCTCATACT  
CTTCCTTTTTCAATATTATTGAAGCATTTA

## References

(1) Tharp, J. M.; Ad, O.; Amikura, K.; Ward, F. R.; Garcia, E. M.; Cate, J. H. D.; Schepartz, A.; Söll, D. Initiation of protein synthesis with non-canonical amino acids in vivo. *Angew. Chem. Int. Ed.* **2020**, *59* (8), 3122–3126.

(2) Wang, Y. S.; Fang, X.; Wallace, A. L.; Wu, B.; Liu, W. R. A rationally designed pyrrolysyl-tRNA synthetase mutant with a broad substrate spectrum. *J. Am. Chem. Soc.* **2012**, *134* (6), 2950–2953.

(3) Chatterjee, A.; Sun, S. B.; Furman, J. L.; Xiao, H.; Schultz, P. G. A versatile platform for single- and multiple-unnatural amino acid mutagenesis in *Escherichia coli*. *Biochemistry* **2013**, *52* (10), 1828–1837.

(4) Ellinger, T.; Ehricht, R. Single-step purification of T7 RNA polymerase with a 6-histidine tag. *Biotechniques* **1998**, *24* (5), 718–720.

(5) Kitagawa, M.; Ara, T.; Arifuzzaman, M.; Ioka-Nakamichi, T.; Inamoto, E.; Toyonaga, H.; Mori, H. Complete set of ORF clones of *Escherichia coli* ASKA library (a complete set of *E. coli* K-12 ORF archive): unique resources for biological research. *DNA Res.* **2005**, *12* (5), 291–299.

(6) Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal. Biochem.* **1976**, *72*, 248–254.

(7) Biddle, W.; Schmitt, M. A.; Fisk, J. D. Evaluating sense codon reassignment with a simple fluorescence screen. *Biochemistry* **2015**, *54*, 7355–7364.